<SEC-DOCUMENT>0001104659-23-007269.txt : 20230127
<SEC-HEADER>0001104659-23-007269.hdr.sgml : 20230127
<ACCEPTANCE-DATETIME>20230127083122
ACCESSION NUMBER:		0001104659-23-007269
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230124
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230127
DATE AS OF CHANGE:		20230127

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PRECIGEN, INC.
		CENTRAL INDEX KEY:			0001356090
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			VA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36042
		FILM NUMBER:		23559740

	BUSINESS ADDRESS:	
		STREET 1:		20374 SENECA MEADOWS PARKWAY
		CITY:			GERMANTOWN
		STATE:			MD
		ZIP:			20876
		BUSINESS PHONE:		301-556-9900

	MAIL ADDRESS:	
		STREET 1:		20374 SENECA MEADOWS PARKWAY
		CITY:			GERMANTOWN
		STATE:			MD
		ZIP:			20876

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTREXON CORP
		DATE OF NAME CHANGE:	20060313
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm234545d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:PGEN="http://precigen.com/20230124">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_03A_PGEN_precigen.com_20230124 -->
<!-- Field: Set; Name: xdx; ID: xdx_04F_20230124_20230124 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DEntityCentralIndexKey_0001356090 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-01-24to2023-01-24" name="dei:EntityCentralIndexKey">0001356090</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-24to2023-01-24" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="pgen-20230124.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-01-24to2023-01-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-24</xbrli:startDate>
        <xbrli:endDate>2023-01-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>



<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90F_edei--DocumentType_c20230124__20230124_z7QNXtbAJpti"><ix:nonNumeric contextRef="From2023-01-24to2023-01-24" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event reported):
<span id="xdx_908_edei--DocumentPeriodEndDate_c20230124__20230124_zYYpk2OUQFy3"><ix:nonNumeric contextRef="From2023-01-24to2023-01-24" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">January 24, 2023</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90C_edei--EntityRegistrantName_c20230124__20230124_zTDYwaosstY6"><ix:nonNumeric contextRef="From2023-01-24to2023-01-24" name="dei:EntityRegistrantName">PRECIGEN, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified in its
charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt; text-align: center; width: 34%"><span style="font-size: 10pt"><b><span id="xdx_906_edei--EntityIncorporationStateCountryCode_c20230124__20230124_zyM3JgG1VKH5"><ix:nonNumeric contextRef="From2023-01-24to2023-01-24" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Virginia</ix:nonNumeric></span></b></span></td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt; text-align: center; width: 32%"><span style="font-size: 10pt"><b><span id="xdx_90A_edei--EntityFileNumber_c20230124__20230124_zzE3m5MQEpbj"><ix:nonNumeric contextRef="From2023-01-24to2023-01-24" name="dei:EntityFileNumber">001-36042</ix:nonNumeric></span></b></span></td>
    <td style="padding: 0.25pt; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt; text-align: center; width: 32%"><span style="font-size: 10pt"><b><span id="xdx_90F_edei--EntityTaxIdentificationNumber_c20230124__20230124_zHzhfFEenRbh"><ix:nonNumeric contextRef="From2023-01-24to2023-01-24" name="dei:EntityTaxIdentificationNumber">26-0084895</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="padding: 0.25pt; vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(State or other jurisdiction</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of incorporation)&#160;</b></p></td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Commission</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>File Number)&#160;</b></p></td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(I.R.S. Employer</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Identification No.)</b></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90C_edei--EntityAddressAddressLine1_c20230124__20230124_zHKjY5TNJL8f"><ix:nonNumeric contextRef="From2023-01-24to2023-01-24" name="dei:EntityAddressAddressLine1">20374 Seneca Meadows Parkway</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressCityOrTown_c20230124__20230124_zVgwxTKmcI07"><ix:nonNumeric contextRef="From2023-01-24to2023-01-24" name="dei:EntityAddressCityOrTown">Germantown</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressStateOrProvince_c20230124__20230124_zB4EDd1AlP1d"><ix:nonNumeric contextRef="From2023-01-24to2023-01-24" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Maryland</ix:nonNumeric></span> <span id="xdx_909_edei--EntityAddressPostalZipCode_c20230124__20230124_zZOrDcCPsZ8c"><ix:nonNumeric contextRef="From2023-01-24to2023-01-24" name="dei:EntityAddressPostalZipCode">20876</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Address of principal executive offices) (Zip
Code)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_909_edei--CityAreaCode_c20230124__20230124_zAjhp2Hz2EQ4"><ix:nonNumeric contextRef="From2023-01-24to2023-01-24" name="dei:CityAreaCode">301</ix:nonNumeric></span>) <span id="xdx_909_edei--LocalPhoneNumber_c20230124__20230124_zhETPcL9N4Qd"><ix:nonNumeric contextRef="From2023-01-24to2023-01-24" name="dei:LocalPhoneNumber">556-9900</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Registrant&#8217;s telephone number, including
area code)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Former name or former address, if changed since
last report)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<span style="text-decoration: underline">see</span> General Instruction
A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt; width: 4%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_90D_edei--WrittenCommunications_c20230124__20230124_z0jDuAdXesf4"><ix:nonNumeric contextRef="From2023-01-24to2023-01-24" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="padding: 0.25pt; font-size: 10pt"><span style="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt; width: 4%; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_90D_edei--SolicitingMaterial_c20230124__20230124_zrtz3mdjxFR1"><ix:nonNumeric contextRef="From2023-01-24to2023-01-24" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td>
    <td style="padding: 0.25pt; font-size: 10pt"><span style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt; width: 4%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_905_edei--PreCommencementTenderOffer_c20230124__20230124_zr7RqlZpRX0d"><ix:nonNumeric contextRef="From2023-01-24to2023-01-24" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="padding: 0.25pt; font-size: 10pt"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt; width: 4%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_908_edei--PreCommencementIssuerTenderOffer_c20230124__20230124_zxq3dbuUeXd4"><ix:nonNumeric contextRef="From2023-01-24to2023-01-24" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="padding: 0.25pt; font-size: 10pt"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Securities registered pursuant to 12(b) of the Act:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 1pt; white-space: nowrap; font-size: 10pt; text-align: center; width: 34%"><span style="font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; width: 32%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Trading</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Symbol(s)&#160;</b></p></td>
    <td style="padding: 0.25pt; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; width: 32%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Name of each exchange</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>on which registered&#160;</b></p></td></tr>
  <tr>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90C_edei--Security12bTitle_c20230124__20230124_z5B0clDAdpbi"><ix:nonNumeric contextRef="From2023-01-24to2023-01-24" name="dei:Security12bTitle">Common Stock, No Par Value</ix:nonNumeric></span></b></span></td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_905_edei--TradingSymbol_c20230124__20230124_zKxgZ2JWLzEa"><ix:nonNumeric contextRef="From2023-01-24to2023-01-24" name="dei:TradingSymbol">PGEN</ix:nonNumeric></span></b></span></td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_908_edei--SecurityExchangeName_c20230124__20230124_zeTSYun4iPI6"><ix:nonNumeric contextRef="From2023-01-24to2023-01-24" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq Global Select Market</ix:nonNumeric></span> </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span style="font-family: Wingdings"><span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20230124__20230124_zpDMcaQnwQai"><ix:nonNumeric contextRef="From2023-01-24to2023-01-24" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b></b></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b></b></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 1in; text-align: left"><span style="font-size: 10pt"><b>Item 1.01</b></span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Entry into a Material Definitive
Agreement.</b></span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 24, 2023, Precigen, Inc. (&#8220;Precigen&#8221;)
entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with J.P. Morgan Securities LLC, as representative
of the several underwriters named therein (the &#8220;Underwriters&#8221;), in connection with the underwritten public offering (the
"Offering") of 42,857,143 shares (the &#8220;Firm Shares&#8221;) of Precigen common stock, no par value (&#8220;Common
Stock&#8221;), at a price to the public of $1.75 per share. Pursuant to the Underwriting Agreement, Precigen granted to the
Underwriters the option to purchase up to an additional 6,428,571 shares of Common Stock (together with the Firm Shares, the
&#8220;Shares&#8221;) for a period of 30 days from the date of the Underwriting Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net proceeds to Precigen from the offering will be approximately $71.2
million after deducting the underwriting discount and other estimated offering expenses payable by Precigen.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Offering was made pursuant to Precigen&#8217;s shelf
registration statement declared effective on July 2, 2020 (Registration No. 333-239366), as supplemented by the final prospectus supplement
dated January 24, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Underwriting Agreement includes certain customary representations,
warranties, and covenants by Precigen, and it provides that Precigen will indemnify the Underwriters against certain liabilities, including
liabilities under the Securities Act of 1933, as amended, or contribute to payments the Underwriters may be required to make because of
any of those liabilities. The representations, warranties, and covenants contained in the Underwriting Agreement were made only for purposes
of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations
agreed upon by the contracting parties. The foregoing description of the Underwriting Agreement does not purport to be complete and is
qualified in its entirety by reference to the Underwriting Agreement, which is filed as Exhibit 1.1 hereto and incorporated herein by
reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A copy of the legal opinion of Hogan Lovells US LLP, Virginia counsel
to Precigen, relating to the legality of the issuance and sale of the Shares is filed as Exhibit 5.1 hereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 1in; text-align: left"><span style="font-size: 10pt"><b>Item 9.01</b></span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Financial Statements and Exhibits.</b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding: 0.25pt; white-space: nowrap; font-size: 10pt; text-align: center; width: 8%"><span style="font-size: 10pt"><b>Exhibit<br />
No.</b></span></td>
    <td style="padding: 0.25pt; width: 2%">&#160;</td>
    <td style="padding: 0.25pt; white-space: nowrap; font-size: 10pt; width: 90%"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr>
    <td style="padding: 0.25pt">&#160;</td>
    <td colspan="2" style="padding: 0.25pt">&#160;</td></tr>
  <tr>
    <td style="padding: 0.25pt; white-space: nowrap; vertical-align: top; font-size: 10pt"><a href="tm234545d1_ex1-1.htm"><span style="font-size: 10pt">1.1</span></a></td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><a href="tm234545d1_ex1-1.htm"><span style="font-size: 10pt">Underwriting Agreement, dated January 24, 2023, between Precigen, Inc. and the Underwriters named therein.</span></a></td></tr>
  <tr>
    <td style="padding: 0.25pt">&#160;</td>
    <td colspan="2" style="padding: 0.25pt">&#160;</td></tr>
  <tr>
    <td style="padding: 0.25pt; white-space: nowrap; vertical-align: top; font-size: 10pt"><a href="tm234545d1_ex5-1.htm"><span style="font-size: 10pt">5.1</span></a></td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><a href="tm234545d1_ex5-1.htm"><span style="font-size: 10pt">Opinion of Hogan Lovells US LLP.</span></a></td></tr>
  <tr>
    <td style="padding: 0.25pt">&#160;</td>
    <td colspan="2" style="padding: 0.25pt">&#160;</td></tr>
  <tr>
    <td style="padding: 0.25pt; white-space: nowrap; vertical-align: top; font-size: 10pt"><a href="tm234545d1_ex5-1.htm"><span style="font-size: 10pt">23.1</span></a></td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><a href="tm234545d1_ex5-1.htm"><span style="font-size: 10pt">Consent of Hogan Lovells US LLP (contained in Exhibit 5.1).</span></a></td></tr>
  <tr>
    <td style="padding: 0.25pt">&#160;</td>
    <td colspan="2" style="padding: 0.25pt">&#160;</td></tr>
  <tr>
    <td style="padding: 0.25pt; white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-size: 10pt">104</span></td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 50%">&#160;</td>
    <td style="padding: 0.25pt; width: 5%">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="padding: 0.25pt; width: 44%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3" style="padding: 0.25pt; font-size: 10pt"><span style="font-size: 10pt"><b>Precigen, Inc.</b></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="padding: 0.25pt">&#160;</td>
    <td colspan="2" style="padding: 0.25pt">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><span style="font-size: 10pt">By:</span></td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top">
    <p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Donald P. Lehr&#160;</p></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><span style="font-size: 10pt">Donald P. Lehr</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><span style="font-size: 10pt">Chief Legal Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: January 27, 2023</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKgkAQRb/Afxj2Ocy1IvAxqYgsQiJ6XXKMJd2R2dXyk/rLNiUaLgzDvWeuEBOxpY2ukOG6yjM4Y91UyiHkWCKjuaFPpLt9An7neNfWsTJuOH9gSp5BzyxCuVTeGKKdtlgkEMlpPPMCKZN5BKeDCL5+SqbUBRqnVQXKFHBialijU9yPH87qRYbqfqi6IFtNJgEZRqP9hjiSMRypU0/ih4UsS0UwGSYQW6a2+da01lEN6wpr32VH9K/gAxXGSUU= -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tm234545d1_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 1.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PRECIGEN,&nbsp;INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">42,857,143 Shares of Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Underwriting Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">January&nbsp;24, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.P.
Morgan Securities LLC<BR>
As Representative of the<BR>
</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>several Underwriters listed<BR>
<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>in Schedule 1 hereto</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o J.P. Morgan Securities LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">383 Madison Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York 10179</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Precigen,&nbsp;Inc., a Virginia corporation (the &ldquo;<U>Company</U>&rdquo;),
proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the &ldquo;<U>Underwriters</U>&rdquo;), for whom you
are acting as representative (the &ldquo;<U>Representative</U>&rdquo;), an aggregate of 42,857,143 shares (the &ldquo;<U>Underwritten
Shares</U>&rdquo;) of Common Stock, no par value per share, of the Company (&ldquo;<U>Common Stock</U>&rdquo;) and, at the option of the
Underwriters, up to an additional 6,428,571 shares of Common Stock (the &ldquo;<U>Option Shares</U>&rdquo;). The Underwritten Shares and
the Option Shares are herein referred to as the &ldquo;<U>Shares</U>&rdquo;. The shares of Common Stock to be outstanding after giving
effect to the sale of the Shares are referred to herein as the &ldquo;<U>Stock</U>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company hereby confirms its agreement with the several Underwriters
concerning the purchase and sale of the Shares, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. <U>Registration Statement</U>. The Company has prepared and filed
with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) under the Securities Act of 1933, as amended, and the
rules&nbsp;and regulations of the Commission thereunder (collectively, the &ldquo;<U>Securities Act</U>&rdquo;), a shelf registration
statement on Form&nbsp;S-3 (File No.&nbsp;333-239366), including a prospectus, relating to the Shares. Such registration statement, as
amended at the time it became effective, including the information, if any, deemed pursuant to Rule&nbsp;430A, 430B or 430C under the
Securities Act to be part of the registration statement at the time of its effectiveness (&ldquo;<U>Rule&nbsp;430 Information</U>&rdquo;),
is referred to herein as the &ldquo;Registration Statement&rdquo;; and as used herein, the term &ldquo;Preliminary Prospectus&rdquo; means
each prospectus included in such registration statement (and any amendments thereto) before effectiveness, any prospectus filed with the
Commission pursuant to Rule&nbsp;424(a)&nbsp;under the Securities Act and the prospectus included in the Registration Statement at the
time of its effectiveness that omits Rule&nbsp;430 Information, and the term &ldquo;Prospectus&rdquo; means the prospectus in the form
first used (or made available upon request of purchasers pursuant to Rule&nbsp;173 under the Securities Act) in connection with confirmation
of sales of the Shares. If the Company has filed an abbreviated registration statement pursuant to Rule&nbsp;462(b)&nbsp;under the Securities
Act (the &ldquo;<U>Rule&nbsp;462 Registration Statement</U>&rdquo;), then any reference herein to the term &ldquo;Registration Statement&rdquo;
shall be deemed to include such Rule&nbsp;462 Registration Statement. Any reference in this underwriting agreement (this &ldquo;<U>Agreement</U>&rdquo;)
to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated
by reference therein pursuant to Item 12 of Form&nbsp;S-3 under the Securities Act, as of the effective date of the Registration Statement
or the date of such Preliminary Prospectus or the Prospectus, as the case may be, and any reference to &ldquo;amend&rdquo;, &ldquo;amendment&rdquo;
or &ldquo;supplement&rdquo; with respect to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to
refer to and include any documents filed after such date under the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and
regulations of the Commission thereunder (collectively, the &ldquo;<U>Exchange Act</U>&rdquo;) that are deemed to be incorporated by reference
therein. Capitalized terms used but not defined herein shall have the meanings given to such terms in the Registration Statement and the
Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At or prior to the Applicable Time (as defined below), the Company
had prepared the following information (collectively with the pricing information set forth on <U>Annex A</U>, the &ldquo;<U>Pricing Disclosure
Package</U>&rdquo;): a Preliminary Prospectus dated January&nbsp;24, 2023 and each &ldquo;free-writing prospectus&rdquo; (as defined pursuant
to Rule&nbsp;405 under the Securities Act) listed on <U>Annex A</U> hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;Applicable Time&rdquo; means 8:30 p.m., New York City time,
on January&nbsp;24, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2. <U>Purchase of the Shares by the Underwriters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a)&nbsp;The Company agrees to issue and sell the Underwritten Shares
to the several Underwriters as provided in this Agreement, and each Underwriter, on the basis of the representations, warranties and agreements
set forth herein and subject to the conditions set forth herein, agrees, severally and not jointly, to purchase at a price per share of
$1.645 (the &ldquo;<U>Purchase Price</U>&rdquo;) from the Company the respective number of Underwritten Shares set forth opposite such
Underwriter&rsquo;s name in Schedule 1 hereto; <I>provided</I>, however, that any Underwritten Shares purchased in the offering by Randal
J. Kirk or entities affiliated with him shall be purchased by the Underwriters from the Company at a price per share equal to $1.75.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, the Company agrees to issue and sell the Option Shares
to the several Underwriters as provided in this Agreement, and the Underwriters, on the basis of the representations, warranties and agreements
set forth herein and subject to the conditions set forth herein, shall have the option to purchase, severally and not jointly, from the
Company the Option Shares at the Purchase Price less an amount per share equal to any dividends or distributions declared by the Company
and payable on the Underwritten Shares but not payable on the Option Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If any Option Shares are to be purchased, the number of Option Shares
to be purchased by each Underwriter shall be the number of Option Shares which bears the same ratio to the aggregate number of Option
Shares being purchased as the number of Underwritten Shares set forth opposite the name of such Underwriter in Schedule 1 hereto (or such
number increased as set forth in Section&nbsp;10 hereof) bears to the aggregate number of Underwritten Shares being purchased from the
Company by the several Underwriters, subject, however, to such adjustments to eliminate any fractional Shares as the Representative in
its sole discretion shall make.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Underwriters may exercise the option to purchase Option Shares
at any time in whole, or from time to time in part, on or before the thirtieth (30th) day following the date of the Prospectus, by written
notice from the Representative to the Company. Such notice shall set forth the aggregate number of Option Shares as to which the option
is being exercised and the date and time when the Option Shares are to be delivered and paid for, which may be the same date and time
as the Closing Date (as hereinafter defined) but shall not be earlier than the Closing Date nor later than the tenth (10th) full business
day (as hereinafter defined) after the date of such notice (unless such time and date are postponed in accordance with the provisions
of Section&nbsp;10 hereof). Any such notice shall be given at least two (2)&nbsp;business days prior to the date and time of delivery
specified therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b)&nbsp;The Company understands that the Underwriters intend to make
a public offering of the Shares, and initially to offer the Shares on the terms set forth in the Pricing Disclosure Package. The Company
acknowledges and agrees that the Underwriters may offer and sell Shares to or through any affiliate of an Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c)&nbsp;Payment for the Shares shall be made by wire transfer in immediately
available funds to the account specified by the Company to the Representative in the case of the Underwritten Shares, at the offices of
Goodwin Procter LLP, The New York Times Building, 620 Eighth Avenue, New York, New York 10018 at 10:00 A.M., New York City time, on January&nbsp;27,
2023, or at such other time or place on the same or such other date, not later than the fifth business day thereafter, as the Representative
and the Company may agree upon in writing or, in the case of the Option Shares, on the date and at the time and place specified by the
Representative in the written notice of the Underwriters&rsquo; election to purchase such Option Shares. The time and date of such payment
for the Underwritten Shares is referred to herein as the &ldquo;Closing Date&rdquo;, and the time and date for such payment for the Option
Shares, if other than the Closing Date, is herein referred to as the &ldquo;Additional Closing Date&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payment for the Shares to be purchased on the Closing Date or the Additional
Closing Date, as the case may be, shall be made against delivery to the Representative for the respective accounts of the several Underwriters
of the Shares to be purchased on such date with any transfer taxes payable in connection with the sale of such Shares duly paid by the
Company. Delivery of the Shares shall be made through the facilities of The Depository Trust Company unless the Representative shall otherwise
instruct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&nbsp;The Company acknowledges and agrees that the Representative
and the other Underwriters are acting solely in the capacity of an arm&rsquo;s length contractual counterparty to the Company with respect
to the offering of Shares contemplated hereby (including in connection with determining the terms of the offering) and not as a financial
advisor or a fiduciary to, or an agent of, the Company or any other person. Additionally, neither the Representative nor any other Underwriter
is advising the Company or any other person as to any legal, tax, investment, accounting or regulatory matters in any jurisdiction. The
Company shall consult with its own advisors concerning such matters and shall be responsible for making its own independent investigation
and appraisal of the transactions contemplated hereby, and neither the Representative nor the Underwriters shall have any responsibility
or liability to the Company with respect thereto. Any review by the Representative and the other Underwriters of the Company, the transactions
contemplated hereby or other matters relating to such transactions will be performed solely for the benefit of the Underwriters and shall
not be on behalf of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3. <U>Representations and Warranties of the Company</U>. The Company
represents and warrants to each Underwriter that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a)&nbsp;<I>Preliminary Prospectus.</I> No order preventing or suspending
the use of any Preliminary Prospectus has been issued by the Commission, and each Preliminary Prospectus included in the Pricing Disclosure
Package, at the time of filing thereof, complied in all material respects with the applicable requirements of the Securities Act, and
no Preliminary Prospectus included in the Pricing Disclosure Package, at the time of filing thereof, contained any untrue statement of
a material fact or omitted to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading; <U>provided</U> that the Company makes no representation or warranty with respect to any statements
or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing
by such Underwriter through the Representative expressly for use in any Preliminary Prospectus, it being understood and agreed that the
only such information furnished by any Underwriter consists of the information described as such in Section&nbsp;7(b)&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b)&nbsp;<I>Pricing Disclosure Package</I>. The Pricing Disclosure
Package as of the Applicable Time did not, and as of the Closing Date and as of the Additional Closing Date, as the case may be, will
not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company makes no representation
or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter
furnished to the Company in writing by such Underwriter through the Representative expressly for use in such Pricing Disclosure Package,
it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such
in Section&nbsp;7(b)&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c)&nbsp;<I>Issuer Free Writing Prospectus. </I>Other than the Registration
Statement, the Preliminary Prospectus and the Prospectus, the Company (including its agents and representatives, other than the Underwriters
in their capacity as such) has not prepared, used, authorized, approved or referred to and will not prepare, use, authorize, approve or
refer to any &ldquo;written communication&rdquo; (as defined in Rule&nbsp;405 under the Securities Act) that constitutes an offer to sell
or solicitation of an offer to buy the Shares (each such communication by the Company or its agents and representatives (other than a
communication referred to in clause (i)&nbsp;below) an &ldquo;<U>Issuer Free Writing Prospectus</U>&rdquo;) other than (i)&nbsp;any document
not constituting a prospectus pursuant to Section&nbsp;2(a)(10)(a)&nbsp;of the Securities Act or Rule&nbsp;134 under the Securities Act
or (ii)&nbsp;the documents listed on <U>Annex A</U> hereto, each electronic road show and any other written communications approved in
writing in advance by the Representative. Each such Issuer Free Writing Prospectus complies in all material respects with the Securities
Act, has been or will be (within the time period specified in Rule&nbsp;433) filed in accordance with the Securities Act (to the extent
required thereby), and, when taken together with the Preliminary Prospectus filed prior to the first use of such Issuer Free Writing Prospectus,
did not, and as of the Closing Date and as of the Additional Closing Date, as the case may be, will not, contain any untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading; <U>provided</U> that the Company makes no representation or warranty with respect to any statements
or omissions made in each such Issuer Free Writing Prospectus or Preliminary Prospectus in reliance upon and in conformity with information
relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representative expressly for use in such
Issuer Free Writing Prospectus or Preliminary Prospectus, it being understood and agreed that the only such information furnished by any
Underwriter consists of the information described as such in Section&nbsp;7(b)&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&nbsp;<I>Registration Statement and Prospectus.</I> The Registration
Statement has been declared effective by the Commission. No order suspending the effectiveness of the Registration Statement has been
issued by the Commission, and no proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act against the Company
or related to the offering of the Shares has been initiated or, to the knowledge of the Company, threatened by the Commission; as of the
applicable effective date of the Registration Statement and any post-effective amendment thereto, the Registration Statement and any such
post-effective amendment complied and will comply in all material respects with the Securities Act, and did not and will not contain any
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements
therein not misleading; and as of the date of the Prospectus and any amendment or supplement thereto and as of the Closing Date and as
of the Additional Closing Date, as the case may be, the Prospectus will comply in all material respects with the Securities Act and will
not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company makes no representation
or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter
furnished to the Company in writing by such Underwriter through the Representative expressly for use in the Registration Statement and
the Prospectus and any amendment or supplement thereto, it being understood and agreed that the only such information furnished by any
Underwriter consists of the information described as such in Section&nbsp;7(b)&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(e)&nbsp;<I>Incorporated Documents.</I> The documents incorporated
by reference in the Registration Statement, the Prospectus and the Pricing Disclosure Package, when they were filed with the Commission
conformed in all material respects to the requirements of the Exchange Act, and none of such documents contained any untrue statement
of a material fact or omitted to state a material fact necessary to make the statements therein, in the light of the circumstances under
which they were made, not misleading; and any further documents so filed and incorporated by reference in the Registration Statement,
the Prospectus or the Pricing Disclosure Package, when such documents are filed with the Commission, will conform in all material respects
to the requirements of the Exchange Act and will not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(f)&nbsp;<I>Financial Statements.</I> The financial statements (including
the related notes thereto) of the Company and its consolidated subsidiaries included or incorporated by reference in the Registration
Statement, the Pricing Disclosure Package and the Prospectus comply in all material respects with the applicable requirements of the Securities
Act and the Exchange Act, as applicable, and present fairly in all material respects the financial position of the Company and its consolidated
subsidiaries as of the dates indicated and the results of their operations and the changes in their cash flows for the periods specified;
such financial statements have been prepared in conformity with generally accepted accounting principles in the United States applied
on a consistent basis throughout the periods covered thereby, except in the case of any unaudited financial statements, which are subject
to normal year-end adjustments and do not contain certain footnotes as permitted by the applicable rules&nbsp;of the Commission, and any
supporting schedules included or incorporated by reference in the Registration Statement present fairly in all material respects the information
required to be stated therein; and the other financial information included or incorporated by reference in the Registration Statement,
the Pricing Disclosure Package and the Prospectus has been derived from the accounting records of the Company and its consolidated subsidiaries
and presents fairly in all material respects the information shown thereby; and the <I>pro forma</I> financial information and the related
notes thereto included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus have
been prepared in accordance with the applicable requirements of the Securities Act and the Exchange Act, as applicable, and the assumptions
underlying such pro forma financial information are reasonable and are set forth in the Registration Statement, the Pricing Disclosure
Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(g)&nbsp;<I>No Material Adverse Change.</I> Since the date of the most
recent financial statements of the Company included or incorporated by reference in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, (i)&nbsp;there has not been any change in the capital stock (other than the issuance of shares of Common Stock
upon exercise of stock options and warrants described as outstanding in, and the grant of options and awards under existing equity incentive
plans described in, the Registration Statement, the Pricing Disclosure Package and the Prospectus), increase in short-term debt (outside
the ordinary course of business) or long-term debt of the Company or any of its subsidiaries, or any dividend or distribution of any kind
declared, set aside for payment, paid or made by the Company on any class of capital stock, or any material adverse change, or any development
involving a prospective material adverse change, in or affecting the business, properties, management, financial position, shareholders&rsquo;
equity or results of operations or prospects of the Company and its subsidiaries taken as a whole; (ii)&nbsp;neither the Company nor any
of its subsidiaries has entered into any transaction or agreement (whether or not in the ordinary course of business) that is material
to the Company and its subsidiaries taken as a whole or incurred any liability or obligation, direct or contingent, that is material to
the Company and its subsidiaries taken as a whole; and (iii)&nbsp;neither the Company nor any of its subsidiaries has sustained any loss
or interference with its business that is material to the Company and its subsidiaries taken as a whole and that is either from fire,
explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance or dispute or any action, order
or decree of any court or arbitrator or governmental or regulatory authority, except in each of clauses (i)-(iii)&nbsp;as otherwise disclosed
in the Registration Statement, the Pricing Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(h)&nbsp;<I>Organization and Good Standing.</I> The Company and each
of its subsidiaries have been duly organized and are validly existing and in good standing (or jurisdictional equivalent) under the laws
of their respective jurisdictions of organization, are duly qualified to do business and are in good standing in each jurisdiction in
which their respective ownership or lease of property or the conduct of their respective businesses requires such qualification, and have
all corporate power and authority necessary to own or hold their respective properties and to conduct the businesses in which they are
engaged, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in
the aggregate, have a material adverse effect on the business, properties, management, financial position, shareholders&rsquo; equity,
results of operations or prospects of the Company and its subsidiaries taken as a whole or on the performance by the Company of its obligations
under this Agreement (a &ldquo;<U>Material Adverse Effect</U>&rdquo;). The Company does not own or control, directly or indirectly, any
corporation, association or other entity that is a significant subsidiary other than the subsidiaries listed in Exhibit&nbsp;21.1 to its
Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2021. For purposes of this Agreement, &ldquo;significant subsidiary&rdquo;
means &ldquo;significant subsidiary,&rdquo; as defined in Rule&nbsp;1-02(w)&nbsp;of Regulation S-K of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(i)&nbsp;<I>Capitalization.</I> The Company has an authorized capitalization
as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading &ldquo;Description of
Capital Stock&rdquo;; all the outstanding shares of capital stock of the Company have been duly and validly authorized and issued and
are fully paid and non-assessable and are not subject to any pre-emptive or similar rights that have not been duly waived or satisfied;
except as described in or expressly contemplated by the Pricing Disclosure Package and the Prospectus, there are no outstanding rights
(including, without limitation, pre-emptive rights), warrants or options to acquire, or instruments convertible into or exchangeable for,
any shares of capital stock or other equity interest in the Company or any of its wholly owned subsidiaries, or any contract, commitment,
agreement, understanding or arrangement of any kind relating to the issuance of any capital stock of the Company or any of its wholly
owned subsidiaries, any such convertible or exchangeable securities or any such rights, warrants or options; and the capital stock of
the Company conforms in all material respects to the description thereof contained in the Registration Statement, the Pricing Disclosure
Package and the Prospectus; and all the outstanding shares of capital stock or other equity interests of each subsidiary owned, directly
or indirectly, by the Company have been duly and validly authorized and issued, are fully paid and non-assessable and are owned directly
or indirectly by the Company, free and clear of any lien, charge, encumbrance, security interest, restriction on voting or transfer or
any other claim of any third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(j)&nbsp;<I>Stock Options. </I>With respect to the outstanding stock
options (the &ldquo;<U>Stock Options</U>&rdquo;) granted pursuant to the stock-based compensation plans of the Company and its subsidiaries
(the &ldquo;<U>Company Stock Plans</U>&rdquo;), (i)&nbsp;each Stock Option intended to qualify as an &ldquo;incentive stock option&rdquo;
under Section&nbsp;422 of the Internal Revenue Code of 1986, as amended (the &ldquo;<U>Code</U>&rdquo;), so qualifies, (ii)&nbsp;each
grant of a Stock Option was duly authorized no later than the date on which the grant of such Stock Option was by its terms to be effective
by all necessary corporate action, including, as applicable, approval by the board of directors of the Company (or a duly constituted
and authorized committee thereof) and any required shareholder approval by the necessary number of votes or written consents, and the
award agreement governing such grant (if any) was duly executed and delivered by each party thereto, (iii)&nbsp;each such grant was made
in all material respects in accordance with the terms of the Company Stock Plans and all applicable laws and regulatory rules&nbsp;or
requirements, and (iv)&nbsp;each such grant was properly accounted for in accordance with GAAP in the financial statements (including
the related notes) of the Company and disclosed in the Company&rsquo;s filings with the Commission in accordance with the Exchange Act
and all other applicable laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(k)&nbsp;<I>Due Authorization.</I> The Company has full corporate right,
power and authority to execute and deliver this Agreement and to perform its obligations hereunder; and all corporate action required
to be taken for the due and proper authorization, execution and delivery by it of this Agreement and the consummation by it of the transactions
contemplated hereby has been duly and validly taken.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(l)&nbsp;<I>Underwriting Agreement. </I>This Agreement has been duly
authorized, executed and delivered by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(m)&nbsp;<I>The Shares. </I>The Shares to be issued and sold by the
Company hereunder have been duly authorized and, when issued and delivered and paid for as provided herein, will be duly and validly issued,
will be fully paid and nonassessable and will conform to the descriptions thereof in the Registration Statement, the Pricing Disclosure
Package and the Prospectus; and the issuance of the Shares is not subject to any preemptive or similar rights that have not been duly
waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(n)&nbsp;<I>No Violation or Default.</I> Neither the Company nor any
of its subsidiaries is (i)&nbsp;in violation of its charter or bylaws or similar organizational documents; (ii)&nbsp;in default, and no
event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or observance of
any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to
which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of
the property or assets of the Company or any of its subsidiaries is subject (collectively, &ldquo;<U>Company Contracts</U>&rdquo;); or
(iii)&nbsp;in violation of any law or statute or any judgment, order, rule&nbsp;or regulation of any court or arbitrator or governmental
or regulatory authority, except, in the case of clauses (ii)&nbsp;and (iii)&nbsp;above, for any such default or violation that would not,
individually or in the aggregate, have a Material Adverse Effect. To the knowledge of the Company, all third parties that are parties
to any Company Contracts are in compliance with the terms, covenants and conditions contained in such Company Contracts, except for any
violation that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(o)&nbsp;<I>No Conflicts. </I>The execution, delivery and performance
by the Company of this Agreement, the issuance and sale of the Shares by the Company and the consummation by the Company of the transactions
contemplated by this Agreement will not (i)&nbsp;conflict with or result in a breach or violation of any of the terms or provisions of,
or constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any property, or assets
of the Company or any of its subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument
to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any
of the property or assets of the Company or any of its subsidiaries is subject, (ii)&nbsp;result in any violation of the provisions of
the charter or by-laws or similar organizational documents of the Company or any of its subsidiaries or (iii)&nbsp;result in the violation
of any law or statute or any judgment, order, rule&nbsp;or regulation of any court or arbitrator or governmental or regulatory authority,
except, in the case of clauses (i)&nbsp;and (iii)&nbsp;above, for any such conflict, breach, violation, or default that would not, individually
or in the aggregate, have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(p)&nbsp;<I>No Consents Required.</I> No consent, approval, authorization,
order, license, registration or qualification of or with any court or arbitrator or governmental or regulatory authority is required for
the execution, delivery and performance by the Company of this Agreement, the issuance and sale of the Shares and the consummation of
the transactions contemplated by this Agreement, except for the registration of the Shares under the Securities Act and such consents,
approvals, authorizations, orders and registrations or qualifications as may be required by the Financial Industry Regulatory Authority,&nbsp;Inc.
(&ldquo;<U>FINRA</U>&rdquo;), the Nasdaq Stock Market LLC (&ldquo;<U>Nasdaq</U>&rdquo;), under applicable state securities laws in connection
with the purchase and distribution of the Shares by the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(q)&nbsp;<I>Legal Proceedings.</I> Except as described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, there are no legal, governmental or regulatory investigations, actions,
suits or proceedings pending to which the Company or any of its subsidiaries is a party or to which any property of the Company or any
of its subsidiaries is the subject that, individually or in the aggregate, if determined adversely to the Company or any of its subsidiaries,
would reasonably be expected to have a Material Adverse Effect; to the knowledge of the Company, no such investigations, actions, suits
or proceedings are threatened or contemplated by any governmental or regulatory authority or threatened by others; and (i)&nbsp;there
are no current or pending legal, governmental or regulatory actions, suits or proceedings that are required under the Securities Act to
be described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus and (ii)&nbsp;there are no statutes, regulations or contracts or other documents
that are required under the Securities Act to be filed as exhibits to the Registration Statement or described in the Registration Statement,
the Pricing Disclosure Package or the Prospectus that are not so filed as exhibits to the Registration Statement or described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(r)&nbsp;<I>Independent Accountants</I>. Deloitte&nbsp;&amp; Touche
LLP who have certified certain financial statements of the Company and its subsidiaries, is an independent registered public accounting
firm with respect to the Company and its subsidiaries within the applicable rules&nbsp;and regulations adopted by the Commission and the
Public Company Accounting Oversight Board (United States) and as required by the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(s)&nbsp;<I>Title to Real and Personal Property</I>. The Company owns
no real property and the Company and its subsidiaries have valid rights to lease or otherwise use, all items of real and personal property
that are material to the respective businesses of the Company and its subsidiaries, in each case free and clear of all liens, encumbrances,
claims and defects and imperfections of title except those that (i)&nbsp;do not materially interfere with the use made and proposed to
be made of such property by the Company and its subsidiaries or (ii)&nbsp;would not reasonably be expected, individually or in the aggregate,
to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(t)&nbsp;<I>Intellectual Property</I>. Except as described, or incorporated
by reference, in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company and its subsidiaries own or
possess adequate rights to use all patents, patent applications, trademarks, service marks, trade names, trademark registrations, service
mark registrations, domain names, goodwill associated with the foregoing, copyrights, licenses, inventions, know-how (including trade
secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures) and other technology
and intellectual property rights (&ldquo;<U>Intellectual Property</U>&rdquo;) necessary for the current conduct of its business as described
in the Registration Statement, the Pricing Disclosure Package and the Prospectus, except where the failure to own or possess adequate
rights to use such Intellectual Property would not reasonably be expected to have a Material Adverse Effect; and, to the knowledge of
the Company, the current conduct of their respective businesses as described in the Registration Statement, the Pricing Disclosure Package
and the Prospectus, does not infringe, misappropriate or otherwise violate any such rights of others, except as would not reasonably be
expected to have a Material Adverse Effect. Except as would not reasonably be expected to have a Material Adverse Effect, neither the
Company nor any of its subsidiaries have received any notice in the past six years or any written notice of any claim of infringement,
misappropriation or other violation of any Intellectual Property of any third party, or any claim challenging the validity, scope, or
enforceability of any Intellectual Property owned by or licensed to the Company or any of its subsidiaries or the Company&rsquo;s or any
such subsidiary&rsquo;s rights therein, excluding office actions before the U.S. Patent and Trademark Office and foreign patent and trademark
offices arising in the ordinary course of prosecuting any pending applications included within such Intellectual Property. Except as would
not reasonably be expected to have a Material Adverse Effect, to the knowledge of the Company, no third party has infringed, misappropriated
or otherwise used Intellectual Property owned by the Company or any of its subsidiaries in conflict with the Company&rsquo;s or any such
subsidiary&rsquo;s rights therein. Except as described, or incorporated by reference, in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, all Intellectual Property owned by the Company or its subsidiaries is owned solely by the Company or the applicable
subsidiary and is owned free and clear of all material liens, encumbrances, defects or other restrictions. Except as would not reasonably
be expected to have a Material Adverse Effect, all licenses pursuant to which any Intellectual Property is licensed to the Company or
any of its subsidiaries are free and clear of all liens and free of any restrictions or defects that would conflict with their respective
businesses. The Company has no knowledge of any specific facts that would support a finding that any of the issued or granted patents
owned by or licensed to the Company or any of its subsidiaries is invalid or unenforceable and, to the knowledge of the Company, all such
issued or granted patents are valid and enforceable. Except as would not reasonably be expected to have a Material Adverse Effect, to
the knowledge of the Company, there is no patent or patent application of any third party that contains claims that would interfere with
a patent or patent application owned by or licensed to the Company or any of its subsidiaries, and no such patent interference has been
provoked or declared. Neither the Company nor any of its subsidiaries is subject to any judgment, order, writ, injunction or decree of
any court or any federal, state, local, foreign or other governmental department, commission, board, bureau, agency or instrumentality,
domestic or foreign, or any arbitrator, nor has it entered into or is it a party to any agreement made in settlement of any pending or
threatened litigation, which materially restricts or impairs their respective use of any Intellectual Property. The Company and its subsidiaries
have taken all reasonable steps necessary to secure interests in the Intellectual Property owned by the Company from their employees,
consultants, agents and contractors, except as would not reasonably be expected to have a Material Adverse Effect. There are no outstanding
options, licenses or agreements of any kind relating to the Intellectual Property owned by the Company or any of its subsidiaries that
are required to be described in the Registration Statement, the Pricing Disclosure Package and the Prospectus and are not described in
all material respects. The Company and its subsidiaries are not a party to or bound by any options, licenses or agreements with respect
to the Intellectual Property of any other person or entity that are required to be described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus and are not described in all material respects. To the knowledge of the Company, no governmental
agency or body or other third party has any claim or right in or to any Intellectual Property owned by the Company or any of its subsidiaries,
except as would not reasonably be expected to have a Material Adverse Effect on the current conduct of its business as described in the
Registration Statement, the Pricing Disclosure Package and the Prospectus. No software governed by a license commonly referred to as an
open source, free software, copyleft or community source code license, including, but not limited to, the GNU General Public License or
GNU Lesser General Public License (such software, &ldquo;<U>Open Source Software</U>&rdquo;), is used by the Company or any of its subsidiaries
in a manner that obligates the Company or any of its subsidiaries to (A)&nbsp;distribute or disclose any other software combined, distributed
or otherwise made available with such Open Source Software in source code form or (B)&nbsp;license or otherwise make available such Open
Source Software and/or other software combined, distributed or otherwise made commercially available with such Open Source Software or
any associated Intellectual Property on a royalty free basis, except as would not reasonably be expected to have a Material Adverse Effect.
The Company and its subsidiaries have taken all reasonable security measures to protect its rights in confidential information and trade
secrets they own, including, without limitation, requiring each employee and consultant and any other person with access to trade secrets
to execute a binding confidentiality agreement and, to the knowledge of the Company, there has not been any breach by any party to such
confidentiality agreements, except where such breach would not reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(u)&nbsp;<I>No Undisclosed Relationships</I>. No relationship, direct
or indirect, exists between or among the Company or any of its subsidiaries, on the one hand, and the directors, officers, shareholders,
customers or suppliers of the Company or any of its subsidiaries, on the other, that is required by the Securities Act to be described
in the Registration Statement and the Prospectus and that is not so described in such documents and in the Pricing Disclosure Package.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(v)&nbsp;<I>Investment Company Act</I>. The Company is not and, after
giving effect to the offering and sale of the Shares and the application of the proceeds thereof as described in the Registration Statement,
the Pricing Disclosure Package and the Prospectus, will not be required to register as an &ldquo;investment company&rdquo; or an entity
 &ldquo;controlled&rdquo; by an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended,
and the rules&nbsp;and regulations of the Commission thereunder (the &ldquo;<U>Investment Company Act</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(w)&nbsp;<I>Taxes.</I> The Company and its subsidiaries have timely
filed all tax returns that are required to have been filed by them pursuant to applicable federal, state, local or foreign law, and have
paid all taxes shown thereon or otherwise assessed, which are due and payable, except assessments against which appeals have been or will
be promptly taken and as to which adequate reserves have been provided and except where failure to file such tax returns or pay such taxes
would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and except as otherwise disclosed,
or incorporated by reference, in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there is no material tax
deficiency that has been, or would reasonably be expected to be, asserted against the Company or any of its subsidiaries or any of their
respective properties or assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(x)&nbsp;<I>Licenses and Permits.</I> The Company and its subsidiaries
possess all licenses, certificates, permits and other authorizations issued by, and have made all declarations and filings with, the appropriate
federal state, local or foreign governmental or regulatory authorities, including, without limitation, all licenses required by the United
States Food and Drug Administration (the &ldquo;FDA&rdquo;) or any component thereof and/or by any other U.S., state, local or foreign
government or drug regulatory agency that are necessary for the ownership or lease of their respective properties or the conduct of their
respective businesses as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, except where the
failure to possess or make the same would not, individually or in the aggregate, have a Material Adverse Effect; and except as described
in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor any of its subsidiaries has
received notice of any revocation or modification of any such license, certificate, permit or authorization or has any reason to believe
that any such license, certificate, permit or authorization will not be renewed in the ordinary course, except where such revocation,
modification or nonrenewal would not reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(y)&nbsp;<I>No Labor Disputes.</I> No labor disturbance by or dispute
with employees of the Company or any of its subsidiaries exists or, to the knowledge of the Company, is contemplated or threatened, and
the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the employees of any of its or its subsidiaries&rsquo;
principal suppliers, contractors or customers, except as would not have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(z)&nbsp;<I>Compliance with and Liability under Environmental Laws.</I>
(i)&nbsp;The Company and its subsidiaries (a)&nbsp;are, and during the past five years were, in compliance with any and all applicable
federal, state, local and foreign laws, rules, regulations, requirements, decisions, judgments, decrees, orders and the common law relating
to pollution or the protection of the environment, natural resources or human health or safety, including those relating to the generation,
storage, treatment, use, handling, transportation, Release (as defined below) or threat of Release of Hazardous Materials (as defined
below) (collectively, &ldquo;<U>Environmental Laws</U>&rdquo;), (b)&nbsp;have received and are in compliance with all permits, licenses,
certificates or other authorizations or approvals required of them under applicable Environmental Laws to conduct their respective businesses,
(c)&nbsp;have not received notice of any actual or potential liability under or relating to, or actual or potential violation of, any
Environmental Laws, including for the investigation or remediation of any Release or threat of Release of Hazardous Materials, and have
no knowledge of any event or condition that would reasonably be expected to result in any such notice, (d)&nbsp;are not conducting or
paying for, in whole or in part, any investigation, remediation or other corrective action pursuant to any Environmental Law at any location,
and (e)&nbsp;are not a party to any order, decree or agreement that imposes any obligation or liability under any Environmental Law, and
(ii)&nbsp;there are no costs or liabilities associated with Environmental Laws of or relating to the Company or its subsidiaries, except
in the case of each of (i)&nbsp;and (ii)&nbsp;above, for any such matter, as would not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect; and (iii)&nbsp;except as described in the Registration Statement, the Pricing Disclosure Package
and the Prospectus, (a)&nbsp;there are no proceedings that are pending, or that are known by the Company to be contemplated, against the
Company or any of its subsidiaries under any Environmental Laws in which a governmental entity is also a party, other than such proceedings
regarding which it is reasonably believed no monetary sanctions of $300,000 or more will be imposed against the Company or any of its
subsidiaries, (b)&nbsp;to the knowledge of the Company, there are no facts or issues regarding compliance with Environmental Laws, or
liabilities or other obligations under Environmental Laws, including the Release or threat of Release of Hazardous Materials, that would
reasonably be expected to have a Material Adverse Effect, and (c)&nbsp;none of the Company and its subsidiaries anticipates material capital
expenditures relating to any Environmental Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(aa) <I>Regulatory Filings</I>. Except as disclosed in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor any of its subsidiaries has failed to file with
(i)&nbsp;any federal, provincial, state, local, municipal, national or international government or governmental authority, regulatory
or administrative agency, governmental commission, department, board, bureau, agency or instrumentality, court, tribunal, arbitrator or
arbitral body (public or private); (ii)&nbsp;any self-regulatory organization; or (iii)&nbsp;any political subdivision of any of the foregoing.
(including, without limitation, the FDA, or any foreign, federal, state, provincial or local Governmental Authority performing functions
similar to those performed by the FDA) (a &ldquo;<U>Governmental Authority</U>&rdquo;) any required filing, declaration, listing, registration,
report or submission, except for such failures that, individually or in the aggregate, would not have a Material Adverse Effect; except
as disclosed in the Registration Statement and the Prospectus, all such filings, declarations, listings, registrations, reports or submissions
were in compliance with applicable laws when filed and no deficiencies have been asserted by any applicable regulatory authority with
respect to any such filings, declarations, listings, registrations, reports or submissions, except for any deficiencies that, individually
or in the aggregate, would not have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(bb) <I>Clinical Studies</I>. T<FONT STYLE="background-color: white">he
preclinical studies and tests and clinical trials described in the </FONT>Registration Statement, the Pricing Disclosure Package and the
Prospectus <FONT STYLE="background-color: white">were, and, if still pending, to the Company&rsquo;s knowledge, are being conducted in
all material respects in accordance with the experimental protocols, procedures and controls pursuant to, where applicable, accepted professional
and scientific standards for products or product candidates comparable to those being developed by the Company; the descriptions of such
studies, tests and trials, and the results thereof, contained in the Prospectus are accurate and complete in all material respects; the
Company is not aware of any tests, studies or trials not described in the </FONT>Registration Statement, the Pricing Disclosure Package
and the Prospectus<FONT STYLE="background-color: white">, the results of which reasonably call into question the results of the tests,
studies and trials described in the </FONT>Registration Statement, the Pricing Disclosure Package and the Prospectus<FONT STYLE="background-color: white">;
and the Company has not received any written notice or correspondence from the FDA or any foreign, state or local Governmental Authority
exercising comparable authority or any institutional review board or comparable authority requiring the termination, suspension, clinical
hold or material modification of any tests, studies or trials,</FONT> except as could not individually or in the aggregate, reasonably
be expected to result in a Material Adverse Effect<FONT STYLE="background-color: white">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(cc) <I>Compliance with Laws</I>. Except as would not, individually
or in the aggregate, reasonably be expected to result in a Material Adverse Effect, the Company and each of its subsidiaries are in compliance
with all applicable laws, regulations and statutes in the jurisdictions in which it carries on business; including applicable Health Care
Laws (defined herein), including, but not limited to, the rules&nbsp;and regulations of the FDA, the U.S. Department of Health and Human
Services Office of Inspector General, the Centers for Medicare&nbsp;&amp; Medicaid Services, the Office for Civil Rights, the Department
of Justice and any other governmental agency or body having jurisdiction over the Company or any of its properties, and has not engaged
in any activities which are, as applicable, cause for false claims liability, civil penalties, or mandatory or permissive exclusion from
Medicare, Medicaid, or any other local, state or federal healthcare program. For purposes of this Agreement, &ldquo;<I><U>Health Care
Laws</U></I>&rdquo; shall mean the federal Anti-kickback Statute (42 U.S.C. &sect; 1320a-7b(b)), the Physician Payments Sunshine Act (42
U.S.C. &sect; 1320a-7h), the civil False Claims Act (31 U.S.C. &sect;&sect; 3729 et seq.), the criminal False Claims Act (42 U.S.C. &sect;
1320a-7b(a)), all criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. Sections 286 and 287,
and the health care fraud criminal provisions under the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. &sect;&sect;
1320d et seq.) (&ldquo;HIPAA&rdquo;), the exclusion laws (42 U.S.C. &sect; 1320a-7), the civil monetary penalties law (42 U.S.C. &sect;
1320a-7a), HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. &sect;&sect; 17921 et
seq.), the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &sect;&sect; 301 et seq.), Medicare (Title XVIII of the Social Security Act),
Medicaid (Title XIX of the Social Security Act), the Public Health Service Act (42 U.S.C. &sect;&sect; 201 et seq.) or the comparable
rules&nbsp;and regulations of any other national, federal, state or local governmental or regulatory body or authority, to the extent
applicable. The Company and its subsidiaries have filed, maintained or submitted all material reports, documents, forms, notices, applications,
records, claims, submissions and supplements or amendments as required by any Health Care Laws, and all such reports, documents, forms,
notices, applications, records, claims, submissions and supplements or amendments were complete and accurate on the date filed in all
material respects (or were corrected or supplemented by a subsequent submission). The Company has not received a notice of non-compliance,
nor knows of, nor has reasonable grounds to know of, any facts that could give rise to a notice of non-compliance with any such laws,
regulations and statutes, and is not aware of any pending change or contemplated change to any applicable law or regulation or governmental
position; in each case that would materially adversely affect the business of the Company or the business or legal environment under which
the Company operates. Each of the Company and its subsidiaries: (A)&nbsp;is and at all times has been in compliance with all statutes,
rules, or regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing,
labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product manufactured or distributed by the Company
or its subsidiaries (&ldquo;<I><U>Applicable Laws</U></I>&rdquo;), except as could not individually or in the aggregate, reasonably be
expected to result in a Material Adverse Effect; (B)&nbsp;has not received any FDA Form&nbsp;483, notice of adverse finding, warning letter,
untitled letter or other correspondence or notice from the FDA or any other Governmental Authority alleging or asserting noncompliance
with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto
required by any such Applicable Laws (&ldquo;<U>Authorizations</U>&rdquo;), except as could not individually or in the aggregate, reasonably
be expected to result in a Material Adverse Effect; (C)&nbsp;possesses all material Authorizations and such Authorizations are valid and
in full force and effect and are not in material violation of any term of any such Authorizations; (D)&nbsp;has not received notice of
any material claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any Governmental Authority
or third party alleging that any product operation or activity is in violation of any Applicable Laws or Authorizations and has no knowledge
that any such Governmental Authority or third party is considering any such claim, litigation, arbitration, action, suit, investigation
or proceeding; (E)&nbsp;has not received notice that any Governmental Authority has taken, is taking or intends to take action to limit,
suspend, modify or revoke any Authorizations material to the operations of the Company and has no knowledge that any such Governmental
Authority is considering such action; (F)&nbsp;confirms that all reports, documents, forms, notices, applications, records, claims, submissions
and supplements or amendments as required by any Applicable Laws or Authorizations were complete and correct on the date filed (or were
corrected or supplemented by a subsequent submission), except as could not individually or in the aggregate, reasonably be expected to
result in a Material Adverse Effect; (G)&nbsp;has not received any written notices or correspondence from the FDA, any foreign, state
or local governmental body exercising comparable authority or any Institutional Review Board alleging or asserting noncompliance with
any applicable Health Care Law or requiring or threatening the termination, suspension, modification or clinical hold of any pre-clinical
studies or clinical trials conducted by or on behalf of the Company or its subsidiaries, except as could not individually or in the aggregate,
reasonably be expected to result in a Material Adverse Effect; and (H)&nbsp;neither the Company and, to the Company&rsquo;s knowledge,
none of its clinical investigators, have been excluded, suspended, disqualified or debarred from participation in any U.S. federal health
care program or human clinical research or is subject to a governmental inquiry, investigation, proceeding, or other similar action that
would reasonably be expected to result in debarment, disqualification, suspension, or exclusion, or convicted of any crime or engaged
in any conduct that would reasonably be expected to result in debarment under 21 U.S.C. &sect; 335a or comparable foreign law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(dd) <I>Hazardous Materials</I>. There has been no storage, generation,
transportation, use, handling, treatment, Release (as defined below) or threat of Release of Hazardous Materials (as defined below) by,
relating to or caused by the Company or any of its subsidiaries (or, to the knowledge of the Company and its subsidiaries, any other entity
(including any predecessor) for whose acts or omissions the Company or any of its subsidiaries is or would reasonably be expected to be
liable) at, on, under or from any property or facility now or, to the knowledge of the Company, previously owned, operated or leased by
the Company or any of its subsidiaries, or, to the knowledge of the Company, at, on, under or from any other property or facility, in
violation of any Environmental Laws or in a manner or amount or to a location that would reasonably be expected to result in any liability
under any Environmental Law, except for any violation or liability which would not, individually or in the aggregate, reasonably be expected
to have a Material Adverse Effect. &ldquo;<U>Hazardous Materials</U>&rdquo; means any material, chemical, substance, waste, pollutant,
contaminant, compound, mixture, or constituent thereof, in any form or amount, including petroleum (including crude oil or any fraction
thereof) and petroleum products, natural gas liquids, asbestos and asbestos containing materials, naturally occurring radioactive materials,
brine, and drilling mud, regulated or which can give rise to liability under any Environmental Law. &ldquo;<U>Release</U>&rdquo; means
any spilling, leaking, seepage, pumping, pouring, emitting, emptying, discharging, injecting, escaping, leaching, dumping, disposing,
depositing, dispersing, or migrating in, into or through the environment, or in, into, from or through any building or structure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(ee) <I>Compliance with ERISA.</I> Except, in each case, for any such
matter as would not, individually, or in the aggregate, reasonably be expected to have a Material Adverse Effect, (i)&nbsp;each employee
benefit plan, within the meaning of Section&nbsp;3(3)&nbsp;of the Employee Retirement Income Security Act of 1974, as amended (&ldquo;<U>ERISA</U>&rdquo;),
for which the Company or any member of its &ldquo;Controlled Group&rdquo; (defined as any organization which is a member of a controlled
group of corporations within the meaning of Section&nbsp;414 of the Code) would have any liability (each, a &ldquo;<U>Plan</U>&rdquo;)
has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules&nbsp;and regulations,
including but not limited to ERISA and the Code; (ii)&nbsp;no prohibited transaction, within the meaning of Section&nbsp;406 of ERISA
or Section&nbsp;4975 of the Code, has occurred with respect to any Plan excluding transactions effected pursuant to a statutory or administrative
exemption; (iii)&nbsp;for each Plan that is subject to the funding rules&nbsp;of Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA,
the minimum funding standard of Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA, as applicable, has been satisfied (without
taking into account any waiver thereof or extension of any amortization period) and is reasonably expected to be satisfied in the future
(without taking into account any waiver thereof or extension of any amortization period); (iv)&nbsp;the fair market value of the assets
of each Plan that is subject to the funding rules&nbsp;of Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA exceeds the present
value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan); (v)&nbsp;no &ldquo;reportable
event&rdquo; (within the meaning of Section&nbsp;4043(c)&nbsp;of ERISA) has occurred or is reasonably expected to occur; (vi)&nbsp;neither
the Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA
(other than contributions to the Plan or premiums to the PBGC, in the ordinary course and without default) in respect of a Plan (including
a &ldquo;multiemployer plan&rdquo;, within the meaning of Section&nbsp;4001(a)(3)&nbsp;of ERISA); and (vii)&nbsp;to the knowledge of the
Company, there is no pending audit or investigation by the Internal Revenue Service, the U.S. Department of Labor, the Pension Benefit
Guaranty Corporation or any other governmental agency or any foreign regulatory agency with respect to any Plan. None of the following
events has occurred or, to the knowledge of the Company, is reasonably likely to occur: (x)&nbsp;a material increase in the aggregate
amount of contributions required to be made to all Plans by the Company or its subsidiaries in the current fiscal year of the Company
and its subsidiaries compared to the amount of such contributions made in the Company and its subsidiaries&rsquo; most recently completed
fiscal year; or (y)&nbsp;an increase that is material to the Company and its subsidiaries, taken as a whole, in the Company and its subsidiaries&rsquo;
 &ldquo;accumulated post-retirement benefit obligations&rdquo; (within the meaning of Statement of Financial Accounting Standards 106)
compared to the amount of such obligations in the Company and its subsidiaries&rsquo; most recently completed fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(ff) <I>Disclosure Controls</I>. The Company maintains an effective
system of &ldquo;disclosure controls and procedures&rdquo; (as defined in Rule&nbsp;13a-15(e)&nbsp;of the Exchange Act) that complies
with the requirements of the Exchange Act and that has been designed to ensure that information required to be disclosed by the Company
in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified
in the Commission&rsquo;s rules&nbsp;and forms, including controls and procedures designed to ensure that such information is accumulated
and communicated to the Company&rsquo;s management as appropriate to allow timely decisions regarding required disclosure. The Company
has carried out evaluations of the effectiveness of their disclosure controls and procedures as required by Rule&nbsp;13a-15 of the Exchange
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(gg) <I>Accounting Controls.</I> The Company and its subsidiaries maintain
systems of &ldquo;internal control over financial reporting&rdquo; (as defined in Rule&nbsp;13a-15(f)&nbsp;of the Exchange Act) that have
been designed to comply with the requirements of the Exchange Act and have been designed by, or under the supervision of, their respective
principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles, including, but not limited to, internal accounting controls sufficient to provide reasonable assurance
that (i)&nbsp;transactions are executed in accordance with management&rsquo;s general or specific authorizations; (ii)&nbsp;transactions
are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and
to maintain asset accountability; (iii)&nbsp;access to assets is permitted only in accordance with management&rsquo;s general or specific
authorization; (iv)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate
action is taken with respect to any differences and (v)&nbsp;interactive data in eXtensible Business Reporting Language included or incorporated
by reference in the Registration Statement, the Prospectus and the Pricing Disclosure Package fairly presents the information called for
in all material respects and is prepared in accordance with the Commission&rsquo;s rules&nbsp;and guidelines applicable thereto. Except
as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no material weaknesses in the
Company&rsquo;s internal control over financial reporting. The Company&rsquo;s auditors and the Audit Committee of the Board of Directors
of the Company have been advised of: (i)&nbsp;all significant deficiencies and material weaknesses in the design or operation of internal
controls over financial reporting which have adversely affected or are reasonably likely to adversely affect the Company&rsquo;s ability
to record, process, summarize and report financial information; and (ii)&nbsp;any fraud, whether or not material, that involves management
or other employees who have a significant role in the Company&rsquo;s internal controls over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(hh) <I>eXtensible Business Reporting Language.</I> The interactive
data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the
information called for in all material respects and has been prepared in accordance with the Commission&rsquo;s rules&nbsp;and guidelines
applicable thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(ii)&nbsp;<I>Insurance. </I>The Company and its subsidiaries have insurance
covering their respective properties, operations, personnel and businesses, including business interruption insurance, which insurance
is in amounts and insures against such losses and risks as the Company reasonably believes are adequate to protect the Company and its
subsidiaries and their respective businesses; and neither the Company nor any of its subsidiaries has (i)&nbsp;received notice from any
insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to be made in order to continue
such insurance or (ii)&nbsp;any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage
expires or to obtain similar coverage at reasonable cost from similar insurers as may be necessary to continue its business in all material
respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(jj) <I>No Unlawful Payments.</I> Neither the Company nor any of its
subsidiaries nor, to the knowledge of the Company, any director, officer, agent, employee, affiliate or other person associated with or
authorized to act on behalf of the Company or any of its subsidiaries has (i)&nbsp;used any corporate funds for any unlawful contribution,
gift, entertainment or other unlawful expense relating to political activity; (ii)&nbsp;made or taken an act in furtherance of an offer,
promise or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee,
including of any government-owned or controlled entity or of a public international organization, or any person acting in an official
capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office; (iii)&nbsp;violated
or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or regulation implementing
the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under
the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or anti-corruption law; or (iv)&nbsp;made, offered, agreed,
requested or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate, payoff,
influence payment, kickback or other unlawful or improper payment or benefit. The Company and its subsidiaries have instituted, maintain
and enforce, and will continue to maintain and enforce policies and procedures designed to promote and ensure compliance with all applicable
anti-bribery and anti-corruption laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(kk) <I>Compliance with Anti-Money Laundering Laws</I>. The operations
of the Company and its subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and
reporting requirements, including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable money
laundering statutes of all jurisdictions where the Company or any of its subsidiaries conducts business, the rules&nbsp;and regulations
thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced by any governmental agency (collectively,
the &ldquo;<U>Anti-Money Laundering Laws</U>&rdquo;) and no action, suit or proceeding by or before any court or governmental agency,
authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is
pending or, to the knowledge of the Company, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(ll) <I>No Conflicts with Sanctions Laws. </I>None of the Company,
any of its subsidiaries, or, to the knowledge of the Company, any director, officer, agent, employee, affiliate or other person associated
with or authorized to act on behalf of the Company or any of its subsidiaries is currently the subject or the target of any sanctions
administered or enforced by the U.S. government, (including, without limitation, the Office of Foreign Assets Control of the U.S. Department
of the Treasury or the U.S. Department of State and including, without limitation, the designation as a &ldquo;specially designated national&rdquo;
or &ldquo;blocked person&rdquo;), the United Nations Security Council, the European Union, His Majesty&rsquo;s Treasury or other relevant
sanctions authority (collectively, &ldquo;<U>Sanctions</U>&rdquo;), nor is the Company, any of its subsidiaries located, organized or
resident in a country or territory that is the subject or target of Sanctions, including, without limitation, the Crimea Region and the
non-government controlled areas of the Zaporizhzhia and Kherson Regions of Ukraine, the so-called Donetsk People&rsquo;s Republic, the
so-called Luhansk People&rsquo;s Republic, Cuba,&nbsp;Iran, North Korea and Syria (each, a &ldquo;<U>Sanctioned Country</U>&rdquo;); and
the Company will not directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise
make available such proceeds to any subsidiary, joint venture partner or other person or entity (i)&nbsp;to fund or facilitate any activities
of or business with any person that, at the time of such funding or facilitation, is the subject or target of Sanctions, (ii)&nbsp;to
fund or facilitate any activities of or business in any Sanctioned Country or (iii)&nbsp;in any other manner that will result in a violation
by any person (including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions.
For the past five years, the Company and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings
or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with
any Sanctioned Country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(mm) <I>No Restrictions on Subsidiaries</I>. No wholly owned subsidiary
is currently prohibited, directly or indirectly, under any agreement or other instrument to which it is a party or is subject, from paying
any dividends to the Company, from making any other distribution on such wholly owned subsidiary&rsquo;s capital stock, from repaying
to the Company any loans or advances to such wholly owned subsidiary from the Company or from transferring any of such wholly owned subsidiary&rsquo;s
properties or assets to the Company or any other subsidiary of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(nn) <I>No Broker&rsquo;s Fees.</I> Neither the Company nor any of
its subsidiaries is a party to any contract, agreement or understanding with any person (other than this Agreement) that would give rise
to a valid claim against the Company or any of its subsidiaries or any Underwriter for a brokerage commission, finder&rsquo;s fee or like
payment in connection with the offering and sale of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(oo) <I>No Registration Rights</I>. No person has the right to require
the Company or any of its subsidiaries to register any securities for sale under the Securities Act by reason of the filing of the Registration
Statement with the Commission or the issuance and sale of the Shares, except for such rights that have been waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(pp) <I>No Stabilization.</I> The Company has not taken, directly or
indirectly, any action designed to or that would reasonably be expected to cause or result in any stabilization or manipulation of the
price of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(qq) <I>Margin Rules</I>. The application of the proceeds received
by the Company from the issuance, sale and delivery of the Shares as described in the Registration Statement, the Pricing Disclosure Package
and the Prospectus will not violate Regulation T, U or X of the Board of Governors of the Federal Reserve System or any other regulation
of such Board of Governors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(rr) <I>Forward-Looking Statements.</I> No forward-looking statement
(within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act) contained in the Registration
Statement, the Pricing Disclosure Package or the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed
other than in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(ss) <I>Statistical and Market Data.</I> Nothing has come to the attention
of the Company that has caused the Company to believe that the statistical and market-related data included or incorporated by reference
in the Registration Statement, the Pricing Disclosure Package and the Prospectus is not based on or derived from sources that are reliable
and accurate in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(tt) <I>Sarbanes-Oxley Act</I>. There is and has been no failure on
the part of the Company or, to the knowledge of the Company, any of the Company&rsquo;s directors or officers, in their capacities as
such, to comply with any applicable provision of the Sarbanes-Oxley Act of 2002, as amended and the rules&nbsp;and regulations promulgated
in connection therewith, including Section&nbsp;402 related to loans and Sections 302 and 906 related to certifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(uu) <I>Status under the Securities Act</I>. At the time of filing
the Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that the Company or any offering
participant made a <I>bona fide</I> offer (within the meaning of Rule&nbsp;164(h)(2)&nbsp;under the Securities Act) of the Shares and
at the date hereof, the Company was not and is not an &ldquo;ineligible issuer.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(vv) <I>No Ratings.</I> There are (and prior to the Closing Date, will
be) no debt securities, convertible securities or preferred stock issued or guaranteed by the Company or any of its subsidiaries that
are rated by a &ldquo;nationally recognized statistical rating organization,&rdquo; as such term is defined in Section&nbsp;3(a)(62) under
the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(ww) <I>Data Protection.</I> Except as would not reasonably be expected
to have a Material Adverse Effect, (i)&nbsp;the Company and each of its subsidiaries have complied with all internal and external written
privacy policies, contractual obligations, and applicable laws, in each case, relating to the collection, use, transfer, import, export,
storage, protection, disposal and disclosure by the Company or any of its subsidiaries of personal, personally identifiable or regulated
data or information (&ldquo;<U>Data Security Obligations</U>&rdquo;, and such data and information, &ldquo;<U>Personal Data</U>&rdquo;),
(ii)&nbsp;the Company and its subsidiaries have not received any written notification of or written complaint regarding and, to the knowledge
of the Company, are unaware of any other facts that, individually or in the aggregate, constitute non-compliance with any Data Security
Obligation by the Company or any of its subsidiaries, and (iii)&nbsp;there is no action, suit or proceeding by or before any court or
governmental agency, authority or body pending or, to the knowledge of the Company, threatened alleging non-compliance with any Data Security
Obligation by the Company or any of its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(xx)&nbsp;<I>Cybersecurity</I>. (i)&nbsp;The Company and its subsidiaries&rsquo;
respective material information technology assets and equipment (including Personal Data and the data and information of their respective
customers, employees, suppliers, vendors and any third party data maintained, processed or stored therein by the Company and its subsidiaries)
used in connection with the operation of the Company&rsquo;s and its subsidiaries&rsquo; respective businesses (&ldquo;<U>IT Systems</U>&rdquo;)
are adequate for, and operate and perform in all material respects as required in connection with the operation of the business of the
Company and its subsidiaries as currently conducted, (ii)&nbsp;the Company and each of its subsidiaries have implemented reasonable technical
and organizational measures designed to protect the IT Systems, and the Company and its subsidiaries have established reasonable information
technology, information security, cyber security and data protection controls, policies and procedures, consistent with industry standards
and practices, that are designed to protect against and prevent unauthorized use, access or disablement by any third party (&ldquo;<U>Breach</U>&rdquo;)
of any IT Systems or Personal Data processed by the Company, and (iii)&nbsp;except as would not reasonably be expected to have a Material
Adverse Effect, there has been no Breach of any IT Systems of Personal Data processed by or on behalf of the Company, and the Company
and its subsidiaries have not been notified in writing of and have no knowledge of any event or condition that would reasonably be expected
to result in, any such Breach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4. <U>Further Agreements of the Company</U>. The Company covenants
and agrees with each Underwriter that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a)&nbsp;<I>Required Filings.</I> The Company will file the final Prospectus
with the Commission within the time periods specified by Rule&nbsp;424(b)&nbsp;and Rule&nbsp;430A, 430B or 430C under the Securities Act,
will file any Issuer Free Writing Prospectus to the extent required by Rule&nbsp;433 under the Securities Act; and the Company will file
promptly all reports and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant
to Section&nbsp;13(a), 13(c), 14 or 15(d)&nbsp;of the Exchange Act subsequent to the date of the Prospectus and for so long as the delivery
of a prospectus is required in connection with the offering or sale of the Shares; and will furnish copies of the Prospectus and each
Issuer Free Writing Prospectus (to the extent not previously delivered) to the Underwriters in New York City prior to 10:00 A.M., New
York City time, on the business day next succeeding the date of this Agreement in such quantities as the Representative may reasonably
request. The Company will pay the registration fee for this offering within the time period required by Rule&nbsp;456(b)(1)&nbsp;under
the Securities Act (without giving effect to the proviso therein) and in any event prior to the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b)&nbsp;<I>Delivery of Copies.</I> The Company will deliver, without
charge, (i)&nbsp;to the Representative, two (2)&nbsp;signed copies of the Registration Statement as originally filed and each amendment
thereto, in each case including all exhibits and consents filed therewith and documents incorporated by reference therein; and (ii)&nbsp;to
each Underwriter (A)&nbsp;a conformed copy of the Registration Statement as originally filed and each amendment thereto (without exhibits)
and (B)&nbsp;during the Prospectus Delivery Period (as defined below), as many copies of the Prospectus (including all amendments and
supplements thereto and documents incorporated by reference therein and each Issuer Free Writing Prospectus) as the Representative may
reasonably request. As used herein, the term &ldquo;Prospectus Delivery Period&rdquo; means such period of time after the first date of
the public offering of the Shares as in the opinion of counsel for the Underwriters a prospectus relating to the Shares is required by
law to be delivered (or required to be delivered but for Rule&nbsp;172 under the Securities Act) in connection with sales of the Shares
by any Underwriter or dealer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c)&nbsp;<I>Amendments or Supplements,&nbsp;Issuer Free Writing Prospectuses.</I>
Before preparing, using, authorizing, approving, referring to or filing any Issuer Free Writing Prospectus, and before filing any amendment
or supplement to the Registration Statement, the Pricing Disclosure Package or the Prospectus, whether before or after the time that the
Registration Statement becomes effective, the Company will furnish to the Representative and counsel for the Underwriters a copy of the
proposed Issuer Free Writing Prospectus, amendment or supplement for review and will not prepare, use, authorize, approve, refer to or
file any such Issuer Free Writing Prospectus or file any such proposed amendment or supplement to which the Representative reasonably
objects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&nbsp;<I>Notice to the Representative.</I> The Company will advise
the Representative promptly, and confirm such advice in writing, (i)&nbsp;when the Registration Statement has become effective; (ii)&nbsp;when
any amendment to the Registration Statement has been filed or becomes effective; (iii)&nbsp;when any supplement to the Pricing Disclosure
Package, the Prospectus or any Issuer Free Writing Prospectus or any amendment to the Prospectus has been filed or distributed; (iv)&nbsp;of
any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus or the
receipt of any comments from the Commission relating to the Registration Statement or any other request by the Commission for any additional
information; (v)&nbsp;of the issuance by the Commission of any order suspending the effectiveness of the Registration Statement or preventing
or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure Package or the Prospectus or the initiation or, to
the knowledge of the Company, threatening of any proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act; (vi)&nbsp;of
the occurrence of any event or development within the Prospectus Delivery Period as a result of which the Prospectus, the Pricing Disclosure
Package or any Issuer Free Writing Prospectus as then amended or supplemented would include any untrue statement of a material fact or
omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus,
the Pricing Disclosure Package or any such Issuer Free Writing Prospectus is delivered to a purchaser, not misleading; (vii)&nbsp;of the
receipt by the Company of any notice of objection of the Commission to the use of the Registration Statement or any post-effective amendment
thereto pursuant to Rule&nbsp;401(g)(2)&nbsp;under the Securities Act; and (viii)&nbsp;of the receipt by the Company of any notice with
respect to any suspension of the qualification of the Shares for offer and sale in any jurisdiction or the initiation or, to the knowledge
of the Company, threatening of any proceeding for such purpose; and the Company will use its commercially reasonable best efforts to prevent
the issuance of any such order suspending the effectiveness of the Registration Statement, preventing or suspending the use of any Preliminary
Prospectus, any of the Pricing Disclosure Package or the Prospectus or suspending any such qualification of the Shares and, if any such
order is issued, will obtain as soon as possible the withdrawal thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(e)&nbsp;<I>Ongoing Compliance.</I> (i)&nbsp;If during the Prospectus
Delivery Period (A)&nbsp;any event or development shall occur or condition shall exist as a result of which the Prospectus as then amended
or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the
statements therein, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, not misleading or (B)&nbsp;it
is necessary to amend or supplement the Prospectus to comply with law, the Company will as soon as practicable, but in no event later
than one (1)&nbsp;business day, notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with
the Commission and furnish to the Underwriters and to such dealers as the Representative may designate such amendments or supplements
to the Prospectus (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that
the statements in the Prospectus as so amended or supplemented (or any document to be filed with the Commission and incorporated by reference
therein) will not, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, be misleading or so that
the Prospectus will comply with law and (ii)&nbsp;if at any time prior to the Closing Date (A)&nbsp;any event or development shall occur
or condition shall exist as a result of which the Pricing Disclosure Package as then amended or supplemented would include any untrue
statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the
circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, not misleading or (B)&nbsp;it is necessary to
amend or supplement the Pricing Disclosure Package to comply with law, the Company will immediately notify the Underwriters thereof and
forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission (to the extent required) and furnish to the Underwriters
and to such dealers as the Representative may designate such amendments or supplements to the Pricing Disclosure Package (or any document
to be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in the Pricing Disclosure
Package as so amended or supplemented will not, in the light of the circumstances existing when the Pricing Disclosure Package is delivered
to a purchaser, be misleading or so that the Pricing Disclosure Package will comply with applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(f)&nbsp;<I>Blue Sky Compliance.</I> The Company will use its commercially
reasonable best efforts, with the Underwriters&rsquo; cooperation, if necessary, to qualify the Shares for offer and sale under the securities
or Blue Sky laws of such jurisdictions as the Representatives shall reasonably request and will use its commercially reasonable best efforts,
with the Underwriters&rsquo; cooperation, if necessary, to continue such qualifications in effect so long as required for distribution
of the Shares; provided that the Company shall not be required to (i)&nbsp;qualify as a foreign corporation or other entity or as a dealer
in securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii)&nbsp;file any general consent to service
of process in any such jurisdiction or (iii)&nbsp;subject itself to taxation in any such jurisdiction if it is not otherwise so subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(g)&nbsp;<I>Earning Statement. </I>The Company will make generally
available to its security holders and the Representative as soon as practicable an earning statement that satisfies the provisions of
Section&nbsp;11(a)&nbsp;of the Securities Act and Rule&nbsp;158 of the Commission promulgated thereunder covering a period of at least
twelve (12) months beginning with the first fiscal quarter of the Company occurring after the &ldquo;effective date&rdquo; (as defined
in Rule&nbsp;158) of the Registration Statement, it being understood and agreed that such earning statement shall be deemed to have been
made available by the Company if the Company is in compliance with its reporting obligations pursuant to the Exchange Act, if such compliance
satisfies the conditions of Rule&nbsp;158, and if such earning statement is made available on the Commission&rsquo;s Electronic Data Gathering,
Analysis and Retrieval system (&ldquo;<U>EDGAR</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(h)&nbsp;<I>Clear Market.</I> For a period of sixty (60) days after
the date of the Prospectus, the Company will not (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly
or indirectly, or file with the Commission a registration statement under the Securities Act relating to, any shares of Stock or any securities
convertible into or exercisable or exchangeable for Stock, or publicly disclose the intention to make any offer, sale, pledge, loan, disposition
or filing (other than filings on Form&nbsp;S-8 relating to Company Stock Plans that are in existence at the Applicable Time and disclosed
in the Prospectus), or (ii)&nbsp;enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences
of ownership of the Stock or any such other securities, whether any such transaction described in clause (i)&nbsp;or (ii)&nbsp;above is
to be settled by delivery of Stock or such other securities, in cash or otherwise, without the prior written consent of the Representative,
other than (A)&nbsp;the Shares to be sold hereunder, (B)&nbsp;any shares of Stock of the Company issued upon the exercise of options granted
or to be granted under the Company Stock Plans, (C)&nbsp;any shares of Stock of the Company issued upon the exercise of warrants or conversion
of convertible notes outstanding on the date of the Prospectus, (D)&nbsp;sales of shares pursuant to the Company&rsquo;s employee stock
purchase plan and grants of equity awards granted or to be granted under Company Stock Plans, in each case for (B)-(D)&nbsp;as described
in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (E)&nbsp;the issuance of up to that number of shares
equal to seven percent (7%) of the Company&rsquo;s outstanding shares of Common Stock, calculated following the sale of Shares hereunder
(&ldquo;<U>Carveout Shares</U>&rdquo;), in connection with mergers or acquisitions of businesses, entities, property or other assets,
joint ventures or strategic alliances, provided that the Company shall cause each such recipient of Carveout Shares to execute and deliver
to the Representatives a lock-up letter substantially in the form of <U>Exhibit&nbsp;A</U> hereto for the balance of the 60-day restricted
period and (F)&nbsp;the filing of a shelf registration statement on Form&nbsp;S-3 (and any amendments thereto) with the Commission so
long as no sales are made under such registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(i)&nbsp;<I>Use of Proceeds.</I> The Company will apply the net proceeds
from the sale of the Shares as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading
 &ldquo;Use of Proceeds&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(j)&nbsp;<I>No Stabilization.</I> The Company will not take, directly
or indirectly, any action designed to or that would reasonably be expected to cause or result in any stabilization or manipulation of
the price of the Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(k)&nbsp;<I>Reports.</I> For a period of three (3)&nbsp;years from
the date of this Agreement, the Company will furnish to the Representative, as soon as commercially reasonable after the date they are
available, copies of all reports or other communications (financial or other) furnished to holders of the Shares, and copies of any reports
and financial statements furnished to or filed with the Commission or any national securities exchange or automatic quotation system;
provided the Company will be deemed to have furnished such reports and financial statements to the Representative to the extent they are
filed on EDGAR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(l)&nbsp;<I>Record Retention</I>. The Company will, pursuant to reasonable
procedures developed in good faith, retain copies of each Issuer Free Writing Prospectus that is not filed with the Commission in accordance
with Rule&nbsp;433 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(m)&nbsp;<I>Shelf Renewal</I>. If immediately prior to the third anniversary
(the &ldquo;<U>Renewal Deadline</U>&rdquo;) of the initial effective date of the Registration Statement, any of the Shares remain unsold
by the Underwriters, the Company will, prior to the Renewal Deadline, file, if it has not already done so and is eligible to do so, a
new automatic shelf registration statement relating to the Shares, in a form satisfactory to the Representative. If the Company is not
eligible to file an automatic shelf registration statement, the Company will, prior to the Renewal Deadline, if it has not already done
so, file a new shelf registration statement relating to the Shares, in a form satisfactory to the Representative, and will use its best
efforts to cause such registration statement to be declared effective within 180 days after the Renewal Deadline. The Company will take
all other action necessary or appropriate to permit the issuance and sale of the Shares to continue as contemplated in the expired registration
statement relating to the Shares. References herein to the Registration Statement shall include such new automatic shelf registration
statement or such new shelf registration statement, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(n)&nbsp;<I>Filings.</I> The Company will file with the Commission
such reports as may be required by Rule&nbsp;463 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(o)&nbsp;<I>Investment Company</I>. The Company will not invest, or
otherwise use the proceeds received by the Company from its sale of the Shares in such a manner as would require the Company to register
as an investment company under the Investment Company Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(p)&nbsp;<I>Transfer Agent</I>. The Company will maintain a transfer
agent and, if necessary under the jurisdiction of incorporation of the Company, a registrar for the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(q)&nbsp;<I>Lock-up Agreements</I>. The Company has caused each officer
and director of the Company to furnish to the Representatives, on or prior to the date of this Agreement, a &ldquo;lock-up&rdquo; agreement,
each substantially in the form of <U>Exhibit&nbsp;A</U> hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5. <U>Certain Agreements of the Underwriters</U>. Each Underwriter
hereby represents and agrees that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a)&nbsp;It has not used, authorized use of, referred to or participated
in the planning for use of, and will not use, authorize use of, refer to or participate in the planning for use of, any &ldquo;free writing
prospectus&rdquo;, as defined in Rule&nbsp;405 under the Securities Act (which term includes use of any written information furnished
to the Commission by the Company and not incorporated by reference into the Registration Statement and any press release issued by the
Company) other than (i)&nbsp;a free writing prospectus that contains no &ldquo;issuer information&rdquo; (as defined in Rule&nbsp;433(h)(2)&nbsp;under
the Securities Act) that was not included (including through incorporation by reference) in the Preliminary Prospectus or a previously
filed Issuer Free Writing Prospectus, (ii)&nbsp;any Issuer Free Writing Prospectus listed on <U>Annex A</U> or prepared pursuant to Section&nbsp;3(c)&nbsp;or
Section&nbsp;4(c)&nbsp;above (including any electronic road show), or (iii)&nbsp;any free writing prospectus prepared by such underwriter
and approved by the Company in advance in writing (each such free writing prospectus referred to in clauses (i)&nbsp;or (iii), an &ldquo;<U>Underwriter
Free Writing Prospectus</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b)&nbsp;It has not and will not, without the prior written consent
of the Company, use any free writing prospectus that contains the final terms of the Shares unless such terms have previously been included
in a free writing prospectus filed with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c)&nbsp;It is not subject to any pending proceeding under Section&nbsp;8A
of the Securities Act with respect to the offering contemplated by this Agreement (and will promptly notify the Company if any such proceeding
against it is initiated during the Prospectus Delivery Period).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">6. <U>Conditions of Underwriters&rsquo; Obligations.</U> The obligation
of each Underwriter to purchase the Underwritten Shares on the Closing Date or the Option Shares on the Additional Closing Date, as the
case may be, as provided herein is subject to the performance by the Company of its covenants and other obligations hereunder and to the
following additional conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a)&nbsp;<I>Registration Compliance; No Stop Order.</I> No order suspending
the effectiveness of the Registration Statement shall be in effect, and no proceeding for such purpose, pursuant to Rule&nbsp;401(g)(2)&nbsp;or
pursuant to Section&nbsp;8A under the Securities Act shall be pending before or threatened by the Commission; the Prospectus and each
Issuer Free Writing Prospectus shall have been timely filed with the Commission under the Securities Act (in the case of an Issuer Free
Writing Prospectus, to the extent required by Rule&nbsp;433 under the Securities Act) and in accordance with Section&nbsp;4(a)&nbsp;hereof;
and all requests by the Commission for additional information shall have been complied with to the reasonable satisfaction of the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b)&nbsp;<I>Representations and Warranties; Covenants.</I> The representations
and warranties of the Company contained herein shall be true and correct on the date hereof and on and as of the Closing Date or the Additional
Closing Date, as the case may be; and the statements of the Company and its officers made in any certificates delivered pursuant to this
Agreement shall be true and correct on and as of the Closing Date or the Additional Closing Date, as the case may be. The Company shall
have performed and complied with all covenants, agreements, obligations and conditions contained in this Agreement that are required to
be performed or complied with by the Company on or before the Closing Date or the Additional Closing Date, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c)&nbsp;<I>No Material Adverse Change.</I> No event or condition of
a type described in Section&nbsp;3(g)&nbsp;hereof shall have occurred or shall exist, which event or condition is not described in the
Pricing Disclosure Package (excluding any amendment or supplement thereto) and the Prospectus (excluding any amendment or supplement thereto)
and the effect of which in the judgment of the Representative makes it impracticable or inadvisable to proceed with the offering, sale
or delivery of the Shares on the Closing Date or the Additional Closing Date, as the case may be, on the terms and in the manner contemplated
by this Agreement, the Pricing Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&nbsp;<I>Officer&rsquo;s Certificate.</I> The Representative shall
have received on and as of the Closing Date or the Additional Closing Date, as the case may be, a certificate of the chief financial officer
or chief accounting officer of the Company and one additional senior executive officer of the Company who is satisfactory to the Representative
(i)&nbsp;confirming that such officers have carefully reviewed the Registration Statement, the Pricing Disclosure Package and the Prospectus
and, to the knowledge of such officers, the representations of the Company set forth in Sections 3(b)&nbsp;and 3(d)&nbsp;hereof are true
and correct, (ii)&nbsp;confirming that the other representations and warranties of the Company in this Agreement are true and correct
and that the Company has complied in all material respects with all agreements and satisfied all conditions on its part to be performed
or satisfied hereunder at or prior to the Closing Date or the Additional Closing Date, as the case may be, and (iii)&nbsp;to the effect
set forth in paragraphs (a)&nbsp;and (c)&nbsp;above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(e)&nbsp;<I>Comfort Letters&nbsp;&amp; CFO Certificate.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(i)&nbsp;On the date of this Agreement and on the Closing Date or the
Additional Closing Date, as the case may be, Deloitte&nbsp;&amp; Touche LLP shall have furnished to the Representative, at the request
of the Company, letters, dated the respective dates of delivery thereof and addressed to the Underwriters, in form and substance reasonably
satisfactory to the Representative, containing statements and information of the type customarily included in accountants&rsquo; &ldquo;comfort
letters&rdquo; to underwriters with respect to the financial statements and certain financial information contained or incorporated by
reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus; provided, that the letter delivered on the
Closing Date or the Additional Closing Date, as the case may be, shall use a &ldquo;cut-off&rdquo; date no more than three (3)&nbsp;business
days prior to such Closing Date or such Additional Closing Date, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(ii)&nbsp;On the date of this Agreement and on the Closing Date or
the Additional Closing Date, as the case may be, the Company shall have furnished to the Representative a certificate, dated the respective
dates of delivery thereof and addressed to the Underwriters, of its chief financial officer with respect to certain financial data contained
in the Pricing Disclosure Package and the Prospectus, providing &ldquo;management comfort&rdquo; with respect to such information, in
form and substance reasonably satisfactory to the Representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(f)&nbsp;<I>Opinion and 10b-5 Statement of Counsel for the Company.</I>
Davis Polk&nbsp;&amp; Wardwell LLP, counsel for the Company, shall have furnished to the Representative, at the request of the Company,
their written opinion and 10b-5 statement, dated the Closing Date or the Additional Closing Date, as the case may be, and addressed to
the Underwriters, in form and substance reasonably satisfactory to the Representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(g)&nbsp;<I>Intellectual Property Opinions of Counsels for the Company</I>.
Barnes&nbsp;&amp; Thornburg LLP and Sterne, Kessler, Goldstein and Fox, each an intellectual property counsel for the Company, and any
other internal intellectual property counsel reasonably satisfactory to the Representative, shall have each furnished to the Representatives,
at the request of the Company, their written opinion, dated the Closing Date or the Additional Closing Date, as the case may be, and addressed
to the Underwriters, covering certain intellectual property matters in form and substance reasonably satisfactory to the Representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(h)&nbsp;<I>Opinion and 10b-5 Statement of Counsel for the Underwriters.</I>
The Representatives shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be, an opinion and
10b-5 statement of Goodwin Procter LLP, counsel for the Underwriters, with respect to such matters as the Representatives may reasonably
request, and such counsel shall have received such documents and information as they may reasonably request to enable them to pass upon
such matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(i)&nbsp;<I>No Legal Impediment to Issuance and Sale.</I> No action
shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any federal, state or foreign
governmental or regulatory authority that would, as of the Closing Date or the Additional Closing Date, as the case may be, prevent the
issuance or sale of the Shares; and no injunction or order of any federal, state or foreign court shall have been issued that would, as
of the Closing Date or the Additional Closing Date, as the case may be, prevent the issuance or sale of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(j)&nbsp;<I>Good Standing</I>. The Representative shall have received
on and as of the Closing Date or the Additional Closing Date, as the case may be, satisfactory evidence of the good standing of the Company
and its subsidiaries in their respective jurisdictions of organization and their good standing as foreign entities in such other jurisdictions
as the Representatives may reasonably request, in each case in writing or any standard form of telecommunication from the appropriate
governmental authorities of such jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(k)&nbsp;<I>Exchange Listing.</I> Nasdaq shall have confirmed as of
the Closing Date or Additional Closing Date, as the case may be, that it has completed its review of any required Notification Form: Listing
of Additional Shares with respect to the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(l)&nbsp;<I>Lock-up Agreements</I>. The &ldquo;lock-up&rdquo; agreements,
each substantially in the form of <U>Exhibit&nbsp;A</U> hereto, between the Representative and certain officers and directors of the Company
relating to sales and certain other dispositions of shares of Stock or certain other securities, delivered to the Representative on or
before the date hereof, shall be in full force and effect on the Closing Date or Additional Closing Date, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(m)&nbsp;<I>Additional Documents.</I> On or prior to the Closing Date
or the Additional Closing Date, as the case may be, the Company shall have furnished to the Representatives such further certificates
and documents as the Representative may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All opinions, letters, certificates and evidence mentioned above or
elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form and substance reasonably
satisfactory to counsel for the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">7. <U>Indemnification and Contribution</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a)&nbsp;<I>Indemnification of the Underwriters.</I> The Company agrees
to indemnify and hold harmless each Underwriter, its affiliates, directors and officers and each person, if any, who controls such Underwriter
within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act, from and against any and all losses,
claims, damages, taxes and liabilities (including, without limitation, reasonable and documented legal fees and other expenses incurred
in connection with any suit, action or proceeding or any claim asserted, as such fees and expenses are incurred), joint or several, that
arise out of, or are based upon, (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration
Statement or caused by any omission or alleged omission to state therein a material fact required to be stated therein or necessary in
order to make the statements therein, not misleading, (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained
in the Prospectus (or any amendment or supplement thereto), any Preliminary Prospectus,&nbsp;Issuer Free Writing Prospectus, any &ldquo;issuer
information&rdquo; filed or required to be filed pursuant to Rule&nbsp;433(d)&nbsp;under the Securities Act, any road show as defined
in Rule&nbsp;433(h)&nbsp;under the Securities Act (a &ldquo;<U>road show</U>&rdquo;) or any Pricing Disclosure Package (including any
Pricing Disclosure Package that has subsequently been amended), or caused by any omission or alleged omission to state therein a material
fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading, in each
case except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any untrue statement or omission or
alleged untrue statement or omission made in reliance upon and in conformity with any information relating to any Underwriter furnished
to the Company in writing by such Underwriter through the Representative expressly for use therein, it being understood and agreed that
the only such information furnished by any Underwriter consists of the information described as such in subsection (b)&nbsp;below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b)&nbsp;<I>Indemnification of the Company.</I> Each Underwriter agrees,
severally and not jointly, to indemnify and hold harmless the Company, its directors, its officers who signed the Registration Statement
and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the
Exchange Act to the same extent as the indemnity set forth in paragraph (a)&nbsp;above, but only with respect to any losses, claims, damages
or liabilities (including, without limitation, reasonable and documented legal fees and other expenses incurred in connection with any
suit, action, or proceeding or any claim asserted, as such fees and expenses are incurred) that arise out of, or are based upon, any untrue
statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to
such Underwriter furnished to the Company in writing by such Underwriter through the Representative expressly for use in the Registration
Statement, the Prospectus (or any amendment or supplement thereto), any Preliminary Prospectus,&nbsp;Issuer Free Writing Prospectus, any
road show or any Pricing Disclosure Package (including any Pricing Disclosure Package that has subsequently been amended), it being understood
and agreed upon that the only such information furnished by any Underwriter consists of the following information in the Prospectus furnished
on behalf of each Underwriter, in each case, under the caption &ldquo;Underwriting&rdquo;, the concession and reallowance figures in the
third paragraph and the information in the ninth, seventeenth, eighteenth paragraphs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c)&nbsp;<I>Notice and Procedures.</I> If any suit, action, proceeding
(including any governmental or regulatory investigation), claim or demand shall be brought or asserted against any person in respect of
which indemnification may be sought pursuant to either paragraph (a)&nbsp;or (b)&nbsp;above, such person (the &ldquo;<U>Indemnified Person</U>&rdquo;)
shall promptly notify the person against whom such indemnification may be sought (the &ldquo;<U>Indemnifying Person</U>&rdquo;) in writing;
<U>provided</U> that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have under paragraph
(a)&nbsp;or (b)&nbsp;above except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or
defenses) by such failure; and <U>provided</U>, <U>further</U>, that the failure to notify the Indemnifying Person shall not relieve it
from any liability that it may have to an Indemnified Person otherwise than under paragraph (a)&nbsp;or (b)&nbsp;above. If any such proceeding
shall be brought or asserted against an Indemnified Person and it shall have notified the Indemnifying Person thereof, the Indemnifying
Person shall retain counsel reasonably satisfactory to the Indemnified Person (who shall not, without the consent of the Indemnified Person,
be counsel to the Indemnifying Person) to represent the Indemnified Person in such proceeding and shall pay the reasonable and documented
fees and expenses of such counsel related to such proceeding, as incurred. In any such proceeding, any Indemnified Person shall have the
right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless (i)&nbsp;the
Indemnifying Person and the Indemnified Person shall have mutually agreed to the contrary; (ii)&nbsp;the Indemnifying Person has failed
within a reasonable time to retain counsel reasonably satisfactory to the Indemnified Person; (iii)&nbsp;the Indemnified Person shall
have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those available to
the Indemnifying Person; or (iv)&nbsp;the named parties in any such proceeding (including any impleaded parties) include both the Indemnifying
Person and the Indemnified Person and representation of both parties by the same counsel would be inappropriate due to actual or potential
differing interest between them. It is understood and agreed that the Indemnifying Person shall not, in connection with any proceeding
or related proceedings in the same jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to any
local counsel) for all Indemnified Persons, and that all such fees and expenses shall be paid or reimbursed as they are incurred. Any
such separate firm for any Underwriter, its affiliates, directors and officers and any control persons of such Underwriter shall be designated
in writing by the Representative and any such separate firm for the Company, its directors, its officers who signed the Registration Statement
and any control persons of the Company shall be designated in writing by the Company. The Indemnifying Person shall not be liable for
any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment
for the plaintiff, the Indemnifying Person agrees to indemnify each Indemnified Person from and against any loss or liability by reason
of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an Indemnified Person shall have requested that
an Indemnifying Person reimburse the Indemnified Person for reasonable and documented fees and expenses of counsel as contemplated by
this paragraph, the Indemnifying Person shall be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such
settlement is entered into more than 45 days after receipt by the Indemnifying Person of such request and (ii)&nbsp;the Indemnifying Person
shall not have reimbursed the Indemnified Person in accordance with such request prior to the date of such settlement. No Indemnifying
Person shall, without the written consent of the Indemnified Person, effect any settlement of any pending or threatened proceeding in
respect of which any Indemnified Person is or could have been a party and indemnification could have been sought hereunder by such Indemnified
Person, unless such settlement (x)&nbsp;includes an unconditional release of such Indemnified Person, in form and substance reasonably
satisfactory to such Indemnified Person, from all liability on claims that are the subject matter of such proceeding and (y)&nbsp;does
not include any statement as to or any admission of fault, culpability or a failure to act by or on behalf of any Indemnified Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&nbsp;<I>Contribution.</I> If the indemnification provided for in
paragraphs (a)&nbsp;or (b)&nbsp;above is unavailable to an Indemnified Person or insufficient in respect of any losses, claims, damages
or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu of indemnifying such Indemnified Person
thereunder, shall contribute to the amount paid or payable by such Indemnified Person as a result of such losses, claims, damages or liabilities
(i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters
on the other, from the offering of the Shares or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;is not permitted by applicable
law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i)&nbsp;but also the relative
fault of the Company, on the one hand, and the Underwriters on the other, in connection with the statements or omissions that resulted
in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative benefits received
by the Company, on the one hand, and the Underwriters on the other, shall be deemed to be in the same respective proportions as the net
proceeds (before deducting expenses) received by the Company from the sale of the Shares and the total underwriting discounts and commissions
received by the Underwriters in connection therewith, in each case as set forth in the table on the cover of the Prospectus, bear to the
aggregate offering price of the Shares. The relative fault of the Company, on the one hand, and the Underwriters on the other, shall be
determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged
omission to state a material fact relates to information supplied by the Company or by the Underwriters and the parties&rsquo; relative
intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(e)&nbsp;<I>Limitation on Liability.</I> The Company and the Underwriters
agree that it would not be just and equitable if contribution pursuant to paragraph (d)&nbsp;above were determined by <U>pro rata</U>
allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take
account of the equitable considerations referred to in paragraph (d)&nbsp;above. The amount paid or payable by an Indemnified Person as
a result of the losses, claims, damages and liabilities referred to in paragraph (d)&nbsp;above shall be deemed to include, subject to
the limitations set forth above, any reasonable and documented legal or other expenses incurred by such Indemnified Person in connection
with any such action or claim. Notwithstanding the provisions of paragraphs (d)&nbsp;and (e), in no event shall an Underwriter be required
to contribute any amount in excess of the amount by which the total underwriting discounts and commissions received by such Underwriter
with respect to the offering of the Shares exceeds the amount of any damages that such Underwriter has otherwise been required to pay
by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation
(within the meaning of Section&nbsp;11(f)&nbsp;of the Securities Act) shall be entitled to contribution from any person who was not guilty
of such fraudulent misrepresentation. The Underwriters&rsquo; obligations to contribute pursuant to paragraphs (d)&nbsp;and (e)&nbsp;are
several in proportion to their respective purchase obligations hereunder and not joint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(f)&nbsp;<I>Non-Exclusive Remedies.</I> The remedies provided for in
this Section&nbsp;7 are not exclusive and shall not limit any rights or remedies which may otherwise be available to any Indemnified Person
at law or in equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8. <U>Effectiveness of Agreement</U>. This Agreement shall become effective
as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">9. <U>Termination</U>. This Agreement may be terminated in the absolute
discretion of the Representative, by notice to the Company, if after the execution and delivery of this Agreement and prior to the Closing
Date or, in the case of the Option Shares, prior to the Additional Closing Date (i)&nbsp;trading generally shall have been suspended or
materially limited on or by either of the New York Stock Exchange or The Nasdaq Stock Market; (ii)&nbsp;trading of any securities issued
or guaranteed by the Company shall have been suspended on any exchange or in any over-the-counter market; (iii)&nbsp;a general moratorium
on commercial banking activities shall have been declared by federal or New York State authorities; or (iv)&nbsp;there shall have occurred
any outbreak or escalation of hostilities or any change in financial markets or any calamity or crisis, either within or outside the United
States, that, in the judgment of the Representative, is material and adverse and makes it impracticable or inadvisable to proceed with
the offering, sale or delivery of the Shares on the Closing Date or the Additional Closing Date, as the case may be, on the terms and
in the manner contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10. <U>Defaulting Underwriter</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a)&nbsp;If, on the Closing Date or the Additional Closing Date, as
the case may be, any Underwriter defaults on its obligation to purchase the Shares that it has agreed to purchase hereunder on such date,
the non-defaulting Underwriters may in their discretion arrange for the purchase of such Shares by other persons satisfactory to the Company
on the terms contained in this Agreement. If, within 36 hours after any such default by any Underwriter, the non-defaulting Underwriters
do not arrange for the purchase of such Shares, then the Company shall be entitled to a further period of 36 hours within which to procure
other persons satisfactory to the non-defaulting Underwriters to purchase such Shares on such terms. If other persons become obligated
or agree to purchase the Shares of a defaulting Underwriter, either the non-defaulting Underwriters or the Company may postpone the Closing
Date or the Additional Closing Date, as the case may be, for up to five (5)&nbsp;full business days in order to effect any changes that
in the opinion of counsel for the Company or counsel for the Underwriters may be necessary in the Registration Statement and the Prospectus
or in any other document or arrangement, and the Company agrees to promptly prepare any amendment or supplement to the Registration Statement
and the Prospectus that effects any such changes. As used in this Agreement, the term &ldquo;Underwriter&rdquo; includes, for all purposes
of this Agreement unless the context otherwise requires, any person not listed in Schedule 1 hereto that, pursuant to this Section&nbsp;10,
purchases Shares that a defaulting Underwriter agreed but failed to purchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b)&nbsp;If, after giving effect to any arrangements for the purchase
of the Shares of a defaulting Underwriter or Underwriters by the non-defaulting Underwriters and the Company as provided in paragraph
(a)&nbsp;above, the aggregate number of Shares that remain unpurchased on the Closing Date or the Additional Closing Date, as the case
may be, does not exceed one-eleventh of the aggregate number of Shares to be purchased on such date, then the Company shall have the right
to require each non-defaulting Underwriter to purchase the number of Shares that such Underwriter agreed to purchase hereunder on such
date plus such Underwriter&rsquo;s pro rata share (based on the number of Shares that such Underwriter agreed to purchase on such date)
of the Shares of such defaulting Underwriter or Underwriters for which such arrangements have not been made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c)&nbsp;If, after giving effect to any arrangements for the purchase
of the Shares of a defaulting Underwriter or Underwriters by the non-defaulting Underwriters and the Company as provided in paragraph
(a)&nbsp;above, the aggregate number of Shares that remain unpurchased on the Closing Date or the Additional Closing Date, as the case
may be, exceeds one-eleventh of the aggregate amount of Shares to be purchased on such date, or if the Company shall not exercise the
right described in paragraph (b)&nbsp;above, then this Agreement or, with respect to any Additional Closing Date, the obligation of the
Underwriters to purchase Shares on the Additional Closing Date shall terminate without liability on the part of the non-defaulting Underwriters.
Any termination of this Agreement pursuant to this Section&nbsp;10 shall be without liability on the part of the Company, except that
the Company and the Underwriters will continue to be liable for the payment of expenses as set forth in Section&nbsp;11 hereof and except
that the provisions of Section&nbsp;7 hereof shall not terminate and shall remain in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&nbsp;Nothing contained herein shall relieve a defaulting Underwriter
of any liability it may have to the Company or any non-defaulting Underwriter for damages caused by its default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">11. <U>Payment of Expenses</U><I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a)&nbsp;Whether or not the transactions contemplated by this Agreement
are consummated or this Agreement is terminated, the Company will pay or cause to be paid all costs and expenses incident to the performance
of its obligations hereunder, including without limitation, (i)&nbsp;the costs incident to the authorization, issuance, sale, preparation
and delivery of the Shares and any taxes payable in that connection; (ii)&nbsp;the costs incident to the preparation, printing and filing
under the Securities Act of the Registration Statement, the Preliminary Prospectus, any Issuer Free Writing Prospectus, any Pricing Disclosure
Package and the Prospectus (including all exhibits, amendments and supplements thereto) and the distribution thereof; (iii)&nbsp;the fees
and expenses of the Company&rsquo;s counsel and independent accountants; (iv)&nbsp;the fees and expenses incurred in connection with the
registration or qualification of the Shares under the state or foreign securities or blue sky laws of such jurisdictions as the Representatives
may designate and the preparation, printing and distribution of a Blue Sky Memorandum (including the related fees and expenses of counsel
for the Underwriters not to exceed $30,000 without the prior written consent of the Company when taken together with the amount incurred
in connection with clause (vii)&nbsp;below); (v)&nbsp;the cost of preparing stock certificates; (vi)&nbsp;the costs and charges of any
transfer agent and any registrar; (vii)&nbsp;all expenses and application fees incurred in connection with any filing with, and clearance
of the offering by, FINRA, in an amount not to exceed $30,000 (exclusive of filing fees) without the prior written consent of the Company
when taken together with the amount incurred in connection with clause (iv)&nbsp;above; (viii)&nbsp;all documented expenses incurred by
the Company in connection with any &ldquo;road show&rdquo; presentation to potential investors; and (ix)&nbsp;all expenses and application
fees related to the listing of the Shares on the Nasdaq Global Select Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b)&nbsp;Except as provided for by this Agreement, the Underwriters
will pay all of their own expenses, including the fees of their counsel and travel and lodging expenses of the Representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c)&nbsp;If (i)&nbsp;this Agreement is terminated pursuant to Section&nbsp;9,
(ii)&nbsp;the Company for any reason fails to tender the Shares for delivery to the Underwriters (other than by reason of a default by
any Underwriter) at the Closing Date or any Additional Closing Date, as applicable, in accordance with this Agreement or (iii)&nbsp;the
Underwriters decline to purchase the Shares because any of the conditions to the Underwriters&rsquo; obligations set forth in Section&nbsp;6
have not been met, the Company agrees to reimburse the Underwriters for all reasonable and documented out-of-pocket costs and expenses
(including the reasonable and documented fees and expenses of their counsel) reasonably incurred by the Underwriters in connection with
this Agreement and the offering contemplated hereby. For the avoidance of doubt, the Company will not pay or reimburse any costs, fees
or expenses incurred by any Underwriter that defaults on its obligations to purchase the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">12. <U>Persons Entitled to Benefit of Agreement</U>. This Agreement
shall inure to the benefit of and be binding upon the parties hereto and their respective successors and the officers and directors and
any controlling persons referred to herein, and the affiliates of each Underwriter referred to in Section&nbsp;7 hereof. Nothing in this
Agreement is intended or shall be construed to give any other person any legal or equitable right, remedy or claim under or in respect
of this Agreement or any provision contained herein. No purchaser of Shares from any Underwriter shall be deemed to be a successor merely
by reason of such purchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">13. <U>Survival</U>. The respective indemnities, rights of contribution,
representations, warranties and agreements of the Company and the Underwriters contained in this Agreement or made by or on behalf of
the Company or the Underwriters pursuant to this Agreement or any certificate delivered pursuant hereto shall survive the delivery of
and payment for the Shares and shall remain in full force and effect, regardless of any termination of this Agreement or any investigation
made by or on behalf of the Company or the Underwriters or the directors, officers, controlling persons or affiliates referred to in Section&nbsp;7
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">14. <U>Certain Defined Terms</U>. For purposes of this Agreement, (a)&nbsp;except
where otherwise expressly provided, the term &ldquo;affiliate&rdquo; has the meaning set forth in Rule&nbsp;405 under the Securities Act;
(b)&nbsp;the term &ldquo;business day&rdquo; means any day other than a day on which banks are permitted or required to be closed in New
York City; and (c)&nbsp;the term &ldquo;subsidiary&rdquo; has the meaning set forth in Rule&nbsp;405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">15. <U>Compliance with USA Patriot Act</U>. In accordance with the
requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October&nbsp;26, 2001)), the Underwriters are required
to obtain, verify and record information that identifies their respective clients, including the Company, which information may include
the name and address of their respective clients, as well as other information that will allow the Underwriters to properly identify their
respective clients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">16. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a)&nbsp;<I>Authority of the Representative</I>. Any action by the
Underwriters hereunder may be taken by the Representative on behalf of the Underwriters, and any such action taken by the Representative
shall be binding upon the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b)&nbsp;<I>Notices.</I> All notices and other communications hereunder
shall be in writing and shall be deemed to have been duly given if mailed or transmitted and confirmed by any standard form of telecommunication.
Notices to the Underwriters shall be given to the Representative: c/o J.P. Morgan Securities LLC, 383 Madison Avenue, New York, New York
10179 (fax: (212) 622-8358); Attention Equity Syndicate Desk with a copy to Goodwin Procter LLP, The New York Times Building, 620 Eighth
Avenue, New York, New York 10018; Attention: Siavosh Salimi. Notices to the Company shall be given to it at Precigen,&nbsp;Inc., 20374
Seneca Meadows Parkway, Germantown, Maryland 20876; Attention: Donald P. Lehr; with a copy to Davis Polk&nbsp;&amp; Wardwell LLP, 450
Lexington Avenue, New York, NY 10017; Attention: Deanna Kirkpatrick and Yasin Keshvargar.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c)&nbsp;<I>Governing Law.</I> This Agreement and any claim, controversy
or dispute arising under or related to this Agreement shall be governed by and construed in accordance with the laws of the State of New
York applicable to agreements made and to be performed in such state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&nbsp;<I>Submission to Jurisdiction</I>. The Company hereby submits
to the exclusive jurisdiction of the U.S. federal and New York state courts in the Borough of Manhattan in The City of New York in any
suit or proceeding arising out of or relating to this Agreement. The Company waives any objection which it may now or hereafter have to
the laying of venue of any such suit or proceeding in such courts. The Company agrees that final judgment in any such suit, action or
proceeding brought in such court shall be conclusive and binding upon the Company and may be enforced in any court to the jurisdiction
of which Company is subject by a suit upon such judgment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(e)&nbsp;<I>Counterparts.</I> This Agreement may be signed in counterparts
(which may include counterparts delivered by any standard form of telecommunication), each of which shall be an original and all of which
together shall constitute one and the same instrument. This Agreement may be delivered via facsimile, electronic mail (including pdf or
any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com or www.echosign.com) or other transmission
method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(f)&nbsp;<I>Amendments or Waivers.</I> No amendment or waiver of any
provision of this Agreement, nor any consent or approval to any departure therefrom, shall in any event be effective unless the same shall
be in writing and signed by the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(g)&nbsp;<I>Waiver of Jury Trial</I>. Each of the parties hereto hereby
waives any right to trial by jury in any suit or proceeding arising out of or relating to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(h)&nbsp;<I>Headings.</I> The headings herein are included for convenience
of reference only and are not intended to be part of, or to affect the meaning or interpretation of, this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(i)<I>&nbsp;Recognition of the U.S. Special Resolution Regimes</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(i)&nbsp;In the event that any Underwriter that is a Covered Entity
becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any
interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the
U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States
or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(ii)&nbsp;In the event that any Underwriter that is a Covered Entity
or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under
this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights
could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state
of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As used in this Section&nbsp;16(g):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;BHC Act Affiliate&rdquo; has the meaning assigned to the term
 &ldquo;affiliate&rdquo; in, and shall be interpreted in accordance with, 12 U.S.C. &sect; 1841(k).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;Covered Entity&rdquo; means any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 9%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a &ldquo;covered entity&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 252.82(b); </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 9%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a &ldquo;covered bank&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 47.3(b); or </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 9%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a &ldquo;covered FSI&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 382.2(b). </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;Default Right&rdquo; has the meaning assigned to that term in,
and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect; 252.81, 47.2 or 382.1, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;U.S. Special Resolution Regime&rdquo; means each of (i)&nbsp;the
Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and
Consumer Protection Act and the regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If the foregoing is in accordance with your understanding, please indicate
your acceptance of this Agreement by signing in the space provided below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding: 0.25pt 0.25pt 0.25pt 10pt; font-size: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRECIGEN,&nbsp;INC.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 0.25pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 0.75pt solid">/s/ Donald P. Lehr</P></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 52%">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; width: 3%">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 0.25pt 0.25pt 10pt; font-size: 10pt; text-indent: -10pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.25pt 0.25pt 10pt; font-size: 10pt; text-indent: -10pt; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Donald P. Lehr</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 0.25pt 0.25pt 10pt; font-size: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.25pt 0.25pt 10pt; font-size: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Legal Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 100%; padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">Accepted: As of the date first written
    above</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">J.P. MORGAN SECURITIES LLC</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">For itself and on behalf of the</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">several Underwriters listed</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">in Schedule 1 hereto.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 5%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 40%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 55%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 0.75pt solid">/s/ David Ke</P></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0.25pt 0.25pt 0.25pt 10pt; font-size: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.25pt 0.25pt 10pt; font-size: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;David Ke</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0.25pt 0.25pt 0.25pt 10pt; font-size: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.25pt 0.25pt 10pt; font-size: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Managing Director</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Schedule 1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Underwriter</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number of<BR> Shares</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 86%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">J.P. Morgan Securities LLC</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">32,142,858</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Cantor Fitzgerald&nbsp;&amp; Co.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,285,714</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">JMP Securities LLC</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,285,714</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">H.C. Wainwright&nbsp;&amp; Co., LLC</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,142,857</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 30pt">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">42,857,143</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Annex A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">a. <B>Pricing Disclosure Package</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">b. <B>Pricing Information Provided Orally by Underwriters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Public offering price: $1.75</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Number of Underwritten Shares: 42,857,143 shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Option Shares: 6,428,571 shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit&nbsp;A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM&nbsp;OF LOCK-UP AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">J.P. MORGAN SECURITIES LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As Representative of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">the several Underwriters listed in</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Schedule 1 to the Underwriting</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Agreement referred to below</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o J.P. Morgan Securities LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">383 Madison Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10179</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Re: Precigen,&nbsp;Inc. &mdash; Public Offering</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned understands that you, as Representative of the several
Underwriters, propose to enter into an Underwriting Agreement (the &ldquo;<U>Underwriting Agreement</U>&rdquo;) with Precigen,&nbsp;Inc.,
a Virginia corporation (the &ldquo;<U>Company</U>&rdquo;), providing for the public offering (the &ldquo;<U>Public Offering</U>&rdquo;)
by the several Underwriters named in Schedule 1 to the Underwriting Agreement (the &ldquo;<U>Underwriters</U>&rdquo;), of Common Stock
of the Company (the &ldquo;<U>Securities</U>&rdquo;). Capitalized terms used herein and not otherwise defined shall have the meanings
set forth in the Underwriting Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In consideration of the Underwriters&rsquo; agreement to purchase and
make the Public Offering of the Securities, and for other good and valuable consideration receipt of which is hereby acknowledged, the
undersigned hereby agrees that, without the prior written consent of the Representative, on behalf of the Underwriters, the undersigned
will not, and will not cause any direct or indirect affiliate to, during the period beginning on the date of this letter agreement (this
 &ldquo;<U>Letter Agreement</U>&rdquo;) and ending at the close of business ninety (90) days after the date of the final prospectus relating
to the Public Offering (the &ldquo;<U>Prospectus</U>&rdquo;) (such period, the &ldquo;<U>Restricted Period</U>&rdquo;), (1)&nbsp;offer,
pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right
or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of common stock, no par value per
share, of the Company (the &ldquo;<U>Common Stock</U>&rdquo;) or any securities convertible into or exercisable or exchangeable for Common
Stock (including without limitation, Common Stock or such other securities which may be deemed to be beneficially owned by the undersigned
in accordance with the rules&nbsp;and regulations of the Securities and Exchange Commission and securities which may be issued upon exercise
of a stock option or warrant) (collectively with the Common Stock, &ldquo;<U>Lock-Up Securities</U>&rdquo;), (2)&nbsp;enter into any hedging,
swap or other agreement or transaction that transfers, in whole or in part, any of the economic consequences of ownership of the Lock-Up
Securities, whether any such transaction described in clause (1)&nbsp;or (2)&nbsp;above is to be settled by delivery of Lock-Up Securities,
in cash or otherwise or (3)&nbsp;make any demand for or exercise any right with respect to the registration of any Lock-Up Securities,
or (4)&nbsp;publicly disclose the intention to do any of the foregoing. The undersigned acknowledges and agrees that the foregoing precludes
the undersigned from engaging in any hedging or other transactions or arrangements (including, without limitation, any short sale or the
purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction
or instrument, however described or defined) designed or intended, or which could reasonably be expected to lead to or result in, a sale
or disposition or transfer (whether by the undersigned or any other person) of any economic consequences of ownership, in whole or in
part, directly or indirectly, of any Lock-Up Securities, whether any such transaction or arrangement (or instrument provided for thereunder)
would be settled by delivery of Lock-Up Securities, in cash or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Notwithstanding the foregoing, the undersigned may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&nbsp; transfer the undersigned&rsquo;s Lock-Up
Securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(i)&nbsp;as a bona fide gift or gifts,
or for bona fide estate planning purposes,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(ii)&nbsp;by will or intestacy,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(iii)&nbsp;to any trust for the direct
or indirect benefit of the undersigned or the immediate family of the undersigned, or if the undersigned is a trust, to a trustor or beneficiary
of the trust or to the estate of a beneficiary of such trust (for purposes of this Letter Agreement, &ldquo;immediate family&rdquo; shall
mean any relationship by blood, current or former marriage, domestic partnership or adoption, not more remote than first cousin),</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(iv)&nbsp;to a partnership, limited liability
company or other entity of which the undersigned or the immediate family of the undersigned are the legal and beneficial owner of all
of the outstanding equity securities or similar interests,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(v)&nbsp;if the undersigned is a corporation,
partnership, limited liability company, trust or other business entity, (A)&nbsp;to another corporation, partnership, limited liability
company, trust or other business entity that is an affiliate (as defined in Rule&nbsp;405 promulgated under the Securities Act of 1933,
as amended) of the undersigned, or to any investment fund or other entity controlling, controlled by, managing or managed by or under
common control with the undersigned or affiliates of the undersigned (including, for the avoidance of doubt, where the undersigned is
a partnership, to its general partner or a successor partnership or fund, or any other funds or other entity controlled or managed by
such partnership), or (B)&nbsp;as part of a distribution to members or shareholders of the undersigned,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(vi)&nbsp;by operation of law, such as
pursuant to a qualified domestic order, divorce settlement, divorce decree or separation agreement,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(vii)&nbsp;to the Company from an employee
of the Company upon death, disability or termination of employment, in each case, of such employee,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(viii)&nbsp;in connection with the vesting,
settlement, or exercise of restricted stock units, options, warrants or other rights to purchase shares of Common Stock (including, in
each case, by way of &ldquo;net&rdquo; or &ldquo;cashless&rdquo; exercise), including for the payment of exercise price and tax and remittance
payments due as a result of the vesting, settlement, or exercise of such restricted stock units, options, warrants or rights, provided
that any such shares of Common Stock received upon such exercise, vesting or settlement shall be subject to the terms of this Letter Agreement,
and provided further that any such restricted stock units, options, warrants or rights are held by the undersigned pursuant to an agreement
or equity awards granted under a stock incentive plan or other equity award plan, each such agreement or plan which is described in the
Registration Statement, the Pricing Disclosure Package and the Prospectus, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(ix)&nbsp;pursuant to a bona fide third-party
tender offer, merger, consolidation or other similar transaction that is approved by the Board of Directors of the Company and made to
all holders of the Company&rsquo;s capital stock involving a Change of Control (as defined below) of the Company (for purposes hereof,
 &ldquo;Change of Control&rdquo; shall mean the transfer (whether by tender offer, merger, consolidation or other similar transaction),
in one transaction or a series of related transactions, to a person or group of affiliated persons, of shares of capital stock if, after
such transfer, such person or group of affiliated persons would hold at least a majority of the outstanding voting securities of the Company
(or the surviving entity)); provided that in the event that such tender offer, merger, consolidation or other similar transaction is not
completed, the undersigned&rsquo;s Lock-Up Securities shall remain subject to the provisions of this Letter Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>provided</U></FONT>
that (A)&nbsp;in the case of any transfer or distribution pursuant to clause (a)(i), (ii), (iii), (iv), (vi)&nbsp;and (vii), such transfer
shall not involve a disposition for value and for (a)(i)-(vii)&nbsp;each donee, devisee, transferee or distributee shall execute and deliver
to the Representative a lock-up letter in the form of this Letter Agreement; (B)&nbsp;in the case of any transfer or distribution pursuant
to clause (a)(i), (ii), (iii), (iv)&nbsp;and (v), no filing by any party (donor, donee, devisee, transferor, transferee, distributer or
distributee) under the Securities Exchange Act of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;), or other public announcement
shall be required or shall be made voluntarily in connection with such transfer or distribution (other than a filing on a Form&nbsp;5
made after the expiration of the Restricted Period referred to above); and (C)&nbsp;in the case of any transfer or distribution pursuant
to clause (a)(vi)&nbsp;and (vii)&nbsp;it shall be a condition to such transfer that no public filing, report or announcement shall be
voluntarily made and if any filing under Section&nbsp;16(a)&nbsp;of the Exchange Act, or other public filing, report or announcement reporting
a reduction in beneficial ownership of shares of Common Stock in connection with such transfer or distribution shall be legally required
during the Restricted Period, such filing, report or announcement shall clearly indicate in the footnotes thereto the nature and conditions
of such transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&nbsp;exercise outstanding options, settle restricted
stock units or other equity awards or exercise warrants pursuant to plans described in the Registration Statement, the Pricing Disclosure
Package and the Prospectus; provided that any Lock-up Securities received upon such exercise, vesting or settlement shall be subject to
the terms of this Letter Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)&nbsp;establish trading plans pursuant to Rule&nbsp;10b5-1
under the Exchange Act for the transfer of shares of Lock-Up Securities; provided that (1)&nbsp;such plans do not provide for the transfer
of Lock-Up Securities during the Restricted Period and (2)&nbsp;no filing by any party under the Exchange Act or other public announcement
shall be required or made voluntarily in connection with such trading plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In furtherance of the foregoing, the Company, and any duly appointed
transfer agent for the registration or transfer of the securities described herein, are hereby authorized to decline to make any transfer
of securities if such transfer would constitute a violation or breach of this Letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned hereby represents and warrants that the undersigned
has full power and authority to enter into this Letter Agreement. All authority herein conferred or agreed to be conferred and any obligations
of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned acknowledges and agrees that the Underwriters have
not provided any recommendation or investment advice nor have the Underwriters solicited any action from the undersigned with respect
to the Public Offering of the Securities and the undersigned has consulted their own legal, accounting, financial, regulatory and tax
advisors to the extent deemed appropriate. The undersigned further acknowledges and agrees that, although the Representative may be required
or choose to provide certain Regulation Best Interest and Form&nbsp;CRS disclosures to you in connection with the Public Offering, the
Representative and the other Underwriters are not making a recommendation to you to enter into this Letter Agreement, and nothing set
forth in such disclosures is intended to suggest that the Representative or any Underwriter is making such a recommendation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned understands that, if the Underwriting Agreement does
not become effective by February&nbsp;3, 2023 or if the Underwriting Agreement (other than the provisions thereof which survive termination)
shall terminate or be terminated prior to payment for and delivery of the Common Stock to be sold thereunder, the undersigned shall be
released from all obligations under this Letter Agreement. The undersigned understands that the Underwriters are entering into the Underwriting
Agreement and proceeding with the Public Offering in reliance upon this Letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned hereby agrees that, to the extent that the terms of
this Letter Agreement conflict with or are in any way inconsistent with any (i)&nbsp;registration rights agreement, (ii)&nbsp;market standoff
agreement or (iii)&nbsp;other lock-up agreement related to the Lock-Up Securities to which the undersigned and the Company may be a party,
this Letter Agreement supersedes such agreements with respect to the Lock-Up Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Letter Agreement and any claim, controversy or dispute arising
under or related to this Letter Agreement shall be governed by and construed in accordance with the laws of the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0.25pt 0.25pt 0.25pt 10pt; font-size: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>NAME OF SHAREHOLDER</I>]</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0.25pt; vertical-align: top; width: 46%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 0.25pt 0.25pt 10pt; font-size: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 0.25pt 0.25pt 10pt; font-size: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>tm234545d1_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 5.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; width: 75%; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="tm234545d1_ex5-1img01.jpg" ALT="HL_color" STYLE="height: 95px; width: 95px"></FONT></TD>
    <TD STYLE="width: 25%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hogan Lovells US LLP</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Harbor East</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">100 International Drive</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Suite&nbsp;2000</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Baltimore, MD 21202</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">T +1 410 659 2700</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">F +1 410 659 2701</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">www.hoganlovells.com</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">January&nbsp;27, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Precigen,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">20374 Seneca Meadows Parkway</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Germantown, Maryland 20876</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the addressee referred to above:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are acting as counsel to
Precigen,&nbsp;Inc., a Virginia corporation (the &ldquo;<B>Company</B>&rdquo;), in connection with its registration statement on
Form&nbsp;S-3, as amended (File No.&nbsp;333-239366) (the &ldquo;<B>Registration Statement</B>&rdquo;), filed with the Securities
and Exchange Commission under the Securities Act of 1933, as amended (the &ldquo;<B>Act</B>&rdquo;) relating to the proposed public
offering of up to 49,285,714 shares of the common stock, no par value per share, of the Company (the &ldquo;<B>Shares</B>&rdquo;),
all of which shares are to be sold by the Company pursuant to the Underwriting Agreement dated January&nbsp;24, 2023 between the
Company and J.P. Morgan Securities LLC as Representative of the several Underwriters named in Schedule 1 thereto (the
 &ldquo;<B>Underwriting Agreement</B>&rdquo;), as described in the prospectus, dated July&nbsp;2, 2020, that forms part of the
Registration Statement (the &ldquo;<B>Registration Statement Prospectus</B>&rdquo;), as supplemented by the Prospectus Supplement,
dated January&nbsp;24, 2023 (together with the Registration Statement Prospectus, the &ldquo;<B>Prospectus</B>&rdquo;). This opinion
letter is furnished to you at your request to enable you to fulfill the requirements of Item&nbsp;601(b)(5)&nbsp;of Regulation S-K,
17&nbsp;C.F.R. &sect;&nbsp;229.601(b)(5), in connection with the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of this opinion letter, we have examined
copies of such agreements, instruments and documents as we have deemed an appropriate basis on which to render the opinions hereinafter
expressed. In our examination of the aforesaid documents, we have assumed the genuineness of all signatures, the legal capacity of all
natural persons, the accuracy and completeness of all documents submitted to us, the authenticity of all original documents, and the conformity
to authentic original documents of all documents submitted to us as copies (including pdfs). As to all matters of fact, we have relied
on the representations and statements of fact made in the documents so reviewed, and we have not independently established the facts so
relied on. This opinion letter is given, and all statements herein are made, in the context of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This opinion letter is based as to matters of
law solely on the Virginia Stock Corporation Act, as amended. We express no opinion herein as to any other statutes, rules&nbsp;or regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 8pt">Hogan Lovells US
LLP is a limited liability partnership registered in the District of Columbia. &ldquo;Hogan Lovells&rdquo; is an international legal
practice that includes Hogan Lovells US LLP and Hogan Lovells International LLP, with offices in: Alicante Amsterdam Baltimore Beijing
Birmingham Boston Brussels Colorado Springs Denver Dubai Dusseldorf Frankfurt Hamburg Hanoi Ho Chi Minh City Hong Kong Houston Johannesburg
London Los Angeles Luxembourg Madrid Mexico City Miami Milan Minneapolis Monterrey Munich New York Northern Virginia Paris Perth Philadelphia
Rome San Francisco S&atilde;o Paulo Shanghai Silicon Valley Singapore Sydney Tokyo Warsaw Washington, D.C. Associated Offices: Budapest
Jakarta Riyadh Shanghai FTZ Ulaanbaatar. Business Service Centers: Johannesburg Louisville. Legal Services Center: Berlin. For more information
see www.hoganlovells.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based upon, subject to and limited by the foregoing,
we are of the opinion that following (i)&nbsp;execution and delivery by the Company of the Underwriting Agreement, (ii)&nbsp;issuance
of the Shares pursuant to the terms of the Underwriting Agreement, and (iii)&nbsp;receipt by the Company of the consideration for the
Shares specified in the resolutions of the Board of Directors and the Pricing Committee of the Board of Directors, the Shares will be
validly issued,&nbsp; fully paid, and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This opinion letter has been prepared for use
in connection with the Registration Statement. We assume no obligation to advise of any changes in the foregoing subsequent to the date
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the filing of this opinion
letter as Exhibit&nbsp;5.1 to the Company&rsquo;s Current Report on Form&nbsp;8-K to be filed with the Securities and Exchange Commission
on the date hereof and to the reference to this firm under the caption &ldquo;Legal Matters&rdquo; in the Prospectus Supplement. In giving
this consent, we do not thereby admit that we are an &ldquo;expert&rdquo; within the meaning of the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ HOGAN LOVELLS US LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">HOGAN LOVELLS US LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>pgen-20230124.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWamCSbOdzZR+WYkxtmBzbVkaPyQuf6qXgiMreNDWIY8L -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:PGEN="http://precigen.com/20230124" elementFormDefault="qualified" targetNamespace="http://precigen.com/20230124">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://precigen.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="pgen-20230124_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="pgen-20230124_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>pgen-20230124_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>pgen-20230124_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://precigen.com/role/Cover" xlink:href="pgen-20230124.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://precigen.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm234545d1_ex5-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm234545d1_ex5-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !? %\# 2(  A$! Q$!_\0
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:(/[@"D[N>Y[5U5%%85J\JJBGLM%_3&E8_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140153554940096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jan. 24, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 24,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36042<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PRECIGEN, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001356090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-0084895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">VA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">20374 Seneca Meadows Parkway<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Germantown<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">556-9900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, No Par Value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PGEN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>tm234545d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="pgen-20230124.xsd" xlink:type="simple"/>
    <context id="From2023-01-24to2023-01-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
        </entity>
        <period>
            <startDate>2023-01-24</startDate>
            <endDate>2023-01-24</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-01-24to2023-01-24">0001356090</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-01-24to2023-01-24">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2023-01-24to2023-01-24">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2023-01-24to2023-01-24">2023-01-24</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2023-01-24to2023-01-24">PRECIGEN, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-01-24to2023-01-24">VA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2023-01-24to2023-01-24">001-36042</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-01-24to2023-01-24">26-0084895</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-01-24to2023-01-24">20374 Seneca Meadows Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2023-01-24to2023-01-24">Germantown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-01-24to2023-01-24">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-01-24to2023-01-24">20876</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-01-24to2023-01-24">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-01-24to2023-01-24">556-9900</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2023-01-24to2023-01-24">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2023-01-24to2023-01-24">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2023-01-24to2023-01-24">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2023-01-24to2023-01-24">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2023-01-24to2023-01-24">Common Stock, No Par Value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-01-24to2023-01-24">PGEN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-01-24to2023-01-24">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-01-24to2023-01-24">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MD=N!XSOO)Q[Y:FWL"7?8S^B*S9GY*PL5C-Q")>8I$YI+011;#IR1?WT3M&Q
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M$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#!!0    ( .M#.U:7BKL<P
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MCEYG>O\P>=0>6N=6RKV'5[+E&''\GN4/4$L#!!0    ( .M#.U8D'INBK0
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ ZT,[5CL.H2SN    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
MZT,[5IE<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " #K0SM6R2+D4$0$  !S$   &
M    @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
MZT,[5I^@&_"Q @  X@P   T              ( !APP  'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    " #K0SM6EXJ[',     3 @  "P              @ %C
M#P  7W)E;',O+G)E;'-02P$"% ,4    " #K0SM6JL0B%C,!   B @  #P
M            @ %,$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ ZT,[
M5B0>FZ*M    ^ $  !H              ( !K!$  'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ ZT,[5F60>9(9 0  SP,  !,
M         ( !D1(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^
) @  VQ,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm234545d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precigen.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm234545d1_8k.htm">tm234545d1_8k.htm</File>
    <File>pgen-20230124.xsd</File>
    <File>pgen-20230124_lab.xml</File>
    <File>pgen-20230124_pre.xml</File>
    <File>tm234545d1_ex1-1.htm</File>
    <File>tm234545d1_ex5-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm234545d1_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "tm234545d1_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pgen-20230124_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pgen-20230124_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "pgen-20230124.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "PGEN",
   "nsuri": "http://precigen.com/20230124",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm234545d1_8k.htm",
      "contextRef": "From2023-01-24to2023-01-24",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://precigen.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm234545d1_8k.htm",
      "contextRef": "From2023-01-24to2023-01-24",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001104659-23-007269-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-23-007269-xbrl.zip
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M4!&F\\Z!KQN[P;V?MOC&_7+O8+5;_@=02P,$%     @ ZT,[5MANE^0+%0
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M)N7L;K90V!1.;OK^1 #4"1HWT79 E/@8N>.&)ZVOJ4(<L\[\TW,^W@#]!FJ
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M1V[<@OAH,.!,QTEVF+QP"7+\GLK[=<]TL*12N4EBWNB8^U_M4/82_.GM6@)
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M0.4JAJL@W-V/(#5^#,A] +V'KA:1NP6;V0>,0"9P10"B/S0JNEU+D^M-']C
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M-(SFOV;AC#>V<RDQ)J.W/0C&=+(LFE4/JV_?:Q*#1SX,=6(J8-B87M3K+A\
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M4/9 $:?MSWI=&7 ?@\M*#,_ N7-"LP[>)%"M"4%)RBP8]'5]>8Q4)6,^5[L
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M;A-+Y_B1IM8K;!74'-YLZV6"A!7*4I(R6MN,R4J#@I>J]M44/D@UECVCHN>
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M%AP2ZRC>["UUHLK.0Q@S_$+S(_\X:>^%-Y[+Q];$TU52[5EAHOB WGCX)2B
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MSMTT0;]63ND&"]9)=?M"5))[2%9UR^FN"N&C-<VW0*AMMTQND]^Z)GE/2-4
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M,NG C9Y#M!_\Q5_O/[:?])-!*"9XU+RVV3AYM&E'?2IFO(LP5,AN%;/:2)^
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MTV,^(U6.6^!^^.#;!I]N9R@A>;-LKSDA^6[/[7 09:8ISH#/^6O>^8' "BB
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MC7F(O1$;"E&<X1,LA20R%*KMK4P%K%V]:UOA-OJ=(&8T8(LC9(MHX! 1+'9
MPM=%'2QE=C,0$K'"C,ML>%8W!O@**AUA!L Z6DJ=(%QNE2<NIV*S2"G7=VS[
MH1,1B)JYZZYH21+H8 %L!EOC#*7+)EM?)2ZLELTH\$&Q"U;KD>%"3P[C.V'P
MIEHX? Z.)^Y*6SE,,G'A@XB>"6,[8! ;!!?32*/:04YU*(DJ2&J[ ]^G@PCQ
ME)3*1)6'0Z;Z-ZVM1PWRNUVS&'^X: UJ?=[+@X,#@KL3T"7N HYN192[04.
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MD6]XC)'YT@A?DQ,C%U7KFN=*73<R-%LAPHFS-,&A)[H,7&QG"[3D)M*47KT
MAY50&-0T$U7 <632X@B'$PVQ ^*5E#NE($/)=N,,I."2^SP&1W$Y1$"TWZ\(
M&TT=)UNR2 D:^A@2*O5M.PXN/8(K;(QR8M,*I48=,^1L*P,(O!(5S$@>R2?8
MZSCFFE$5P8/(;M+DMC3!)U)B:XPX S,1_)+0?LS*M@Z^C34[<JZWIV<2DG/
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MCH?+S QDOQLL^,C]O(%#Y\^O7=3Q19?C%,9A*<]'(>*$L@1#<VPW)^*(H9L
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MD#$^MO<;N6+H84^1BE(<6[YE]7=QTH.;E]83"<7X32:R][ 7T;&RW" W!:)
MY237HT$V2Y)*DI&"L'$2(2QOC/%KUI]XYI L96BV@Y_ "PJJBG!K>Q3/5]-'
MW_' %U)7DI@YAT-E>U4]AJI3(L2.B+D13B+_,ED;CFA/AJ!^0HFT852'X]J.
M*LF9Z\9-0=H,AY<0<)4CAI:<K4#O(2+K0RS+86+ G.%-BHD=%9?(C:=_T9&O
MAX'-2YC$>C2[E@2BF2&5TC($</0MX"0!$NM$1'XFWX";;9(0>+.&Y43T= 6#
M.0M( G6G5>3U"TW0"X.RPG/$C+CUBTEYV*EF(UB.91RACI0UAH[5PEP[-$?*
M[3+'V&>,;!N3F^0<!/9&>8\IDV%YF0SJ<CR!IS8=94<>E]B4$09W"\[C&5-#
M4S$@$'C)3=G?=FX^Y[OT)^&8987M9DOH>R;'[>4H*&)]YH;\B<&()8+RJ8UE
M_P: VN9448@>L.I)OYETAGO5V;@'B%4>;Z"] (8%1<ESKG<!JRS)^_A_#$AC
MZ#'2Z+ D#<5/J"2NTD*X-FV&\%V&.PI2K%@IQN#PB9]CIK>F&A+?,)'/F;!5
MCPM4C$!-L\&4TO'! :<-Z4RRN>@:Q%2#N%Y^N^]:2XK"E@-4'NGYTE3EXM/0
M>4F [US4=4Z0(3MR.4H/"B1/6?\8YGHG_2/!"$XT4/0KSR:4"C2&<BQ_+?C&
MM=EO?WDO0JY>$-M3YRFFU$(O$&H^W%:LF4"0;%!1L.?_E^7B#9?=TVE&BM)U
M3[UM6UU9D_L$#O$TI?UGXWE]_;55BBR4%;(ZGLGW2CP(.SAX[+$-D)N@$D N
M1UI=9XOE!^ZYB'C3/<UO^&V;U?]2:0;^$YF2G<W'3$F+,R7+ \MZ\_M;/8]8
M,R%066).F7")'-)>Q/8:1W:](A[KR[H7FI8E1.MK*=9AI/)?_M\4_VL\0B*O
MF-*?/%U&%3U2><;72<+NL\GRXAW!!4!:@L OW' \)3)78M#5&"5-X/SB#_H*
M=A/-+!*ACT;;L ?_I,=*PM04?Y4J;Z-@@%H$E*R4L,F2$;=&HYJPL8'[K#"-
MY;8E=A=WG>JE\ ( A8Q5A5@:@!9&L 9+DZ%#W;!"^#>[6J&S5CB\U15G[=;K
MPU>F;,C&L9XQVPN'L<H56N[G2Y6TJO:E"C@:#K,):"VV=(V]GJ/1FG.0QOR2
M+!F0H0GL6XZAVQJ_SY.^RN*O96K(@X&M:XF1A> #;#6O]B[6DL*+;&%A\FV4
M^K6IE5(_KR.#:G;@KJ1].UBBC%2/FSS;\70P^@H7O4:F_/4@Q8!5=[SXO  A
M#'Z$U2D4/K/;89ZYNN(N.B\.DB_Q+&0566[*'*&1J7FDV;MR496%6X;#OZ8:
M3O13XTE/V8[+T7FMS6IP).\L-F9Q*2$PF!GQA+-C:V0K0B&Z<*%5[H'IEI-(
M,\&)54'9&)0GE34Q$SS^=AB-T<'"73"[75# R)M(BVL^&CRKKFI\$V!P+%?C
M6;.'[WC@H#FL"U[O^19>W,+XYNZ%A^YOU>T-[N;UKJXTN[UE\]D4$DT\^W4Y
M@0XN=9L?Z2 =]>"$I*=" I(!BJ,@@2<)X1UT]]3F:;8VN[L;6U*@7]%&)HAF
ME8"K/ZI>1GDO3?4F.V\L2AD9/O+!RBOHP-;X+_-T"E\J6AW:8! T3/$>=^]=
MKERS RU6.]1N(O$\2QM5J50ZT$RA,M7'2"X4C489YF\Q8*E2 @=]:(7'KXG-
M/6$BC]K99*-FN/TGE. @=XQ,QI?@P/_)]D2<]&"/J?7+E.QZ,N0\-BU= 1(@
M0-\;7'BRAX-IF@W,$-$W8UZ[6@W1ZKTL5P3+ZN5JW7-9L-'UIC#8*ZU'YL2+
M"8C^*+L1&CY9?DP%>]UV]2L4[&.?AOF*='/!BHM%F$E-NI;\V[^H=&5P'/N1
MO<3+H6%S-+LIWX1T,7"(1A*BV-5$E(_PPV62<BZ2@T31P*X(^3MU><D'M<^W
M5GY[?8'8-[>ZXBCB6"IT,/\-[HLY"DZR/8JGF#<!M\JVW7D/Q6!(CPH,*,[*
MZI!2>.7-<VOG&[N/ZKLURH]"4<63/!D(;V.:H\'+9FE('2*@J#D5GPY!OZ7X
M:^D*R?*9YH' @(;YH=286JEO6(&OK2D4:![E&&FLEMUK-F3>)L!8!E@'W[^L
M<[>EM\0:T5C-?IE)=ZO>EKTD'V, [\PTM03O8'N"(ZF@H7=:M^W@[%R;"B9X
M:<.39MFD[KZJ6?]0\QM^6$"V@"]-;_M15U,U5G3%\?&2-,G;%U ?H?9]7G)4
M%F3$='22)G<G17R)7'7/SEV_CRMAY+[<4<SU$,[(\0DR9D[_E ;^H-1 N;$Z
MU"K"AG;?.,,&$-RV+DX:I!ZVG_J4T'SZD'3S293/>-@[8;"]N;WCE"8V]1 [
M(852@%FZ,B2CQM'TQ$W6KZO5I;]+N+;1_CN6'E$\%Y+=O<AR-Z8U<\+WUL65
M;B%,"]AN@FH5MO7P\X0(-J4?AEI-[*5D#,K:Z^^V;:DJ3SP]="ZXY::F27MU
MQ:ZPY&)[<(-J%UZM#DVQ57>0DEDG%^1?Q*#Q-*NOL<T"JZ.';E_-M,GJ@.62
M7B[J1DFTW0D+$=(A=3T7]%3Z#*7P-,3D6;::S;8ZS%9%PXRN$G!(<?^S"QB.
MEV%VBHSYW&C@U7[*Y-QXGC7^$?REOL13%;8F(.6BX0*S6=BT-,4$#:4DQM21
MEQ,O:AO?JB-JN4S5S5E-S]X@2J^U=!#423'3QE[R%7)097@:60%0VY:S.[6+
MJ;9J'Q\G_:P2J,)VIUJ><:ZVC6YLVZJ6;BOL2JN7>*&DW-9C4NZ')>7:006F
M+_@N#N!&,MPVL/,LGVGY[MR_/W:5?RCEV?^\.7I[LO_I,/C\(3C_=?_L\-?/
MQ^\/S]X\/7K[OS^%<OF.2UW]IE+-;=Y"P7LO=CE+6+M4OMK;B.9N RJO#+MV
M<CKTY\TD?$V+\]]%B5OADGM<HO(25:G;_D(D9SO;KP,&FRU>!<=8K]8"N^@_
M4#]D/E;YR--WG]__@3O\]-<OGX[?_C]02P,$%     @ ZT,[5I(DNR/P"@
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ML[NWNQ>V_Y />XVVFDU:[>;G>%*CT][PU]I5[P\8;VSITJGD@![2Z[WXH;2
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M,#(S,#$R-"YX<V102P$"% ,4    " #K0SM6+LQ\.OX*  " A@  %0
M        @ &" P  <&=E;BTR,#(S,#$R-%]L86(N>&UL4$L! A0#%     @
MZT,[5KU?$6I7!P  U5<  !4              ( !LPX  '!G96XM,C R,S Q
M,C1?<')E+GAM;%!+ 0(4 Q0    ( .M#.U;8;I?D"Q4  )5W   1
M      "  3T6  !T;3(S-#4T-60Q7SAK+FAT;5!+ 0(4 Q0    ( .M#.U96
M("IPL*   &LO P 4              "  7<K  !T;3(S-#4T-60Q7V5X,2TQ
M+FAT;5!+ 0(4 Q0    ( .M#.U:2)+LC\ H  *<E   4              "
M 5G,  !T;3(S-#4T-60Q7V5X-2TQ+FAT;5!+!08     !@ & (@!  ![UP
"   !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
